<SEC-DOCUMENT>0001193125-25-272532.txt : 20251107
<SEC-HEADER>0001193125-25-272532.hdr.sgml : 20251107
<ACCEPTANCE-DATETIME>20251107165732
ACCESSION NUMBER:		0001193125-25-272532
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20251107
DATE AS OF CHANGE:		20251107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MiNK Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291388
		FILM NUMBER:		251463414

	BUSINESS ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010
		BUSINESS PHONE:		212-994-8250

	MAIL ADDRESS:	
		STREET 1:		149 FIFTH AVENUE
		STREET 2:		SUITE 500
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AgenTus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20210112
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>d62147ds3.htm
<DESCRIPTION>S-3
<TEXT>
<HTML><HEAD>
<TITLE>S-3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on November&nbsp;7, 2025. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-&#8195;&#8195;&#8195;</FONT> </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">S-3</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">82-2142067</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>149 Fifth Street, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10010 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">994-8250</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of
registrant&#8217;s principal executive offices) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jennifer S. Buell, Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President, Chief Executive Officer and Director </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>149 Fifth Street, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10010 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">994-8250</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for
service) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Peter N.
Handrinos </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wesley C. Holmes </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Elisabeth M. Martin </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham&nbsp;&amp; Watkins LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>200 Clarendon Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston, MA 02116 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(617) <FONT
STYLE="white-space:nowrap">948-6000</FONT></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>From time to time after the effective date of this Registration Statement. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis
pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&#8194;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the
following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this
Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.&#8194;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed
to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
<FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company&#8221; and &#8220;emerging growth company&#8221; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&#8194;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration
statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPLANATORY NOTE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This registration statement contains: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a base prospectus, which covers the offering, issuance and sale by us of up to $150,000,000 in the aggregate of
the registrant&#8217;s common stock, preferred stock, warrants, debt securities and/or units from time to time in one or more offerings; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a prospectus supplement, which covers the offering, issuance and sale by us of up to $50,000,000 in the aggregate
of shares of our common stock that may be issued and sold under an At Market Issuance Sales Agreement with B. Riley Securities, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base
prospectus will be specified in a prospectus supplement to the base prospectus. The prospectus supplement immediately follows the base prospectus. The $150,000,000 of shares of common stock that may be offered, issued and sold under the prospectus
supplement is included in the $50,000,000 of securities that may be offered, issued and sold by us under the base prospectus. Upon termination of the At Market Issuance Sales Agreement with B. Riley Securities, Inc., any portion of the $50,000,000
included in the prospectus supplement that is not sold pursuant to the At Market Issuance Sales Agreement will be available for sale in other offerings pursuant to the base prospectus, and if no shares of common stock are sold under the At Market
Issuance Sales Agreement, the full $150,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#ff4338"><B>The information contained in this prospectus is not complete and may be changed. We may not sell these securities until the registration
statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where such offer or sale is not permitted.
</B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED NOVEMBER&nbsp;7, 2025 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g62147g04x33.jpg" ALT="LOGO" STYLE="width:3.03472in;height:0.972222in;">
 </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We may offer to the public from time to time in one or more series or issuances: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">warrants to purchase our common stock, preferred stock or debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">debt securities consisting of debentures, notes or other evidences of indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">units consisting of a combination of the foregoing securities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:8pt">any combination of these securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The aggregate initial offering price of all securities sold by us pursuant to this prospectus will not exceed $150,000,000. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">This prospectus provides a general description of the securities that we may offer. Each time that we offer securities under this prospectus, we
will provide the specific terms of the securities offered, including the public offering price, in a supplement to this prospectus. Any prospectus supplement may add to, update or change information contained in this prospectus. You should carefully
read this prospectus as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you purchase any of the securities offered hereby. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The securities may be sold by us to or through underwriters or dealers, directly to purchasers or through agents designated from time to time.
For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this prospectus and the comparable section of any applicable prospectus supplement. If any underwriters are involved in
the sale of the securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in the applicable prospectus supplement.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Capital Market under the symbol &#8220;INKT.&#8221; On November&nbsp;6, 2025, the closing price of
our common stock was $13.66. We have not yet determined whether the other securities that may be offered by this prospectus will be listed on any exchange, interdealer quotation system or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market. If we decide to seek the listing of any such securities upon issuance, the prospectus supplement relating to those securities will disclose the exchange, quotation system or market on
which those securities will be listed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">As of November&nbsp;6, 2025, the aggregate market value of our outstanding common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates,</FONT> or our public float, was approximately $35,031,699&nbsp;based on 2,149,184 shares of outstanding common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of such date, at a
price of $16.30 per share on September&nbsp;22, 2025, which was the highest closing sale price of our common stock on the Nasdaq Capital Market within 60 days of the filing date of this registration statement. During the prior 12 calendar month
period that ends on and includes the date of this prospectus, we have offered and sold 163,660 shares of common stock for gross proceeds of $5,035,949 pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT>
Pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> in no event will we sell securities registered on this registration statement in a public primary offering with a value exceeding more than <FONT
STYLE="white-space:nowrap">one-third</FONT> of our public float in any <FONT STYLE="white-space:nowrap">12-month</FONT> period so long as our public float remains below $75.0&nbsp;million. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. Risks associated with an investment in our securities will be described in the
applicable prospectus supplement and certain of our filings with the Securities and Exchange Commission incorporated by reference into this prospectus, as described under &#8220;<A HREF="#toca62147_3">Risk Factors</A>&#8221; on page 5. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>You should read this prospectus and any applicable prospectus supplement together with additional information described under the heading
&#8220;Where You Can Find More Information&#8221; before you make your investment decision. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is&#8195;&#8195;&#8195;&#8195;&#8195;. </B></P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_6">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_7">GENERAL DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_8">DESCRIPTION OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_9">DESCRIPTION OF OUR PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_10">DESCRIPTION OF OUR WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_11">DESCRIPTION OF OUR DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_12">DESCRIPTION OF OUR UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_14">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca62147_15">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&#8220;shelf&#8221; registration process. Under this shelf registration process, we may offer to sell any of the securities, or any combination of the securities, described in this prospectus, in each case in one or more offerings, up to a total
dollar amount of $150,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you only with a general description of the securities that we may offer. Each
time securities are sold under the shelf registration statement, we will provide a prospectus supplement that will contain specific information about the terms of those securities and the terms of that offering. The prospectus supplement may also
add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and any prospectus supplement, you should rely on the information in the prospectus supplement. You should read
both this prospectus and any prospectus supplement, including all documents incorporated by reference herein and therein, together with the additional information described under &#8220;Where You Can Find More Information&#8221; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information contained in this prospectus is not complete and may be changed. You should rely only on the information provided in or
incorporated by reference in this prospectus or in any prospectus supplement, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained
or incorporated by reference in this prospectus and any accompanying prospectus supplement. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or an accompanying prospectus
supplement. This prospectus and the accompanying prospectus supplement, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this
prospectus and the accompanying prospectus supplement, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such
jurisdiction. You should not assume that the information contained in this prospectus and the accompanying prospectus supplement, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information
we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a later date.
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Trademarks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
contains references to our trademarks and service marks and to those belonging to other entities. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or
sponsorship of us by, any other entity. Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may be listed without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, SM and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market and Industry Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated, information contained in this prospectus and any accompanying prospectus supplement concerning our industry and the markets in which we operate, including our general expectations, market position and market opportunity, is
based on our management&#8217;s estimates and research, as well as industry and general publications and research, surveys and studies conducted by third parties. We believe that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the information from these third-party publications, research, surveys and studies included in this prospectus and any accompanying prospectus supplement is reliable. Management&#8217;s estimates
are derived from publicly available information, their knowledge of our industry and their assumptions based on such information and knowledge, which we believe to be reasonable. This data involves a number of assumptions and limitations which are
necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;Risk Factors.&#8221; These and other factors could cause our future performance to differ materially from our assumptions
and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">References in this prospectus to the terms &#8220;the Company,&#8221; &#8220;MiNK,&#8221; &#8220;we,&#8221;
&#8220;our&#8221; and &#8220;us&#8221; or other similar terms mean MiNK Therapeutics, Inc. and its subsidiaries, unless we state otherwise or the context indicates otherwise. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus. The summary may not contain
all the information that you should consider before investing in our securities. You should read the entire prospectus carefully, including &#8220;Risk Factors&#8221; contained in this prospectus and the documents incorporated by reference herein,
before making an investment decision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> invariant natural killer T (iNKT) cell therapies designed
to treat cancer and immune-mediated diseases. Our therapies are based on a proprietary platform of allogeneic, <FONT STYLE="white-space:nowrap">ex-vivo</FONT> expanded iNKT cells&#8212;cells that are designed to uniquely combine the precision and
memory of adaptive T cells with the speed and potency of natural killer (NK) cells. This rare biology is designed to allow iNKT cells to navigate tissues, eliminate tumors and infected cells, and reprogram the immune environment&#8212;all without
graft-versus-host disease (GVHD). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe iNKT cells represent an optimal platform for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> cellular immunotherapy. Unlike conventional T or NK cell therapies, our iNKT cells can persist without lymphodepletion and function without the need for human leukocyte antigen (HLA) matching.
This allows for scalable, repeatable, and widely accessible treatment options in indications with significant unmet need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach
includes the development of both native and engineered iNKT cell therapies. Our pipeline includes wholly owned and exclusively licensed assets targeting solid tumors, pulmonary immune failure, and immune-related disorders. We have also developed a
proprietary neoantigen library that supports personalized TCR development by identifying patient-specific tumor signatures. These insights can be used to create highly tailored <FONT STYLE="white-space:nowrap">TCR-iNKT</FONT> therapies, enabling
precision targeting across cancers and complex immune pathologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate,
<FONT STYLE="white-space:nowrap">agenT-797,</FONT> is an allogeneic, native iNKT cell therapy in development for both oncology and immune-mediated diseases. In a clinical trial (NCT05108623) involving patients with treatment-refractory solid tumors,
<FONT STYLE="white-space:nowrap">agenT-797</FONT> was evaluated as monotherapy and in combination with <FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors nivolumab or pembrolizumab. Treatment was associated with reductions in target and <FONT
STYLE="white-space:nowrap">non-target</FONT> lesions and durable disease stabilization, including a partial response in a patient with checkpoint-refractory gastric cancer. <FONT STYLE="white-space:nowrap">AgenT-797</FONT> also demonstrated
long-term persistence in the bloodstream&#8212;up to six months&#8212;without HLA matching or lymphodepletion. The therapy was well tolerated, with no cases of cytokine release syndrome (CRS) or GVHD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in 2024. Preclinical data from the same program
demonstrated that <FONT STYLE="white-space:nowrap">agenT-797,</FONT> when combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, or DLL3, enhanced tumor cell killing, T cell activation, and reduced exhaustion markers&#8212;supporting
potential future combination strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further peer-reviewed data support the clinical activity of
<FONT STYLE="white-space:nowrap">agenT-797.</FONT> A case report published in <I>Oncogene</I> in January&nbsp;2024 described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free
survival after a single infusion of <FONT STYLE="white-space:nowrap">agenT-797</FONT> plus nivolumab. More recently, on July&nbsp;11, 2025, a landmark <I>Oncogene</I> publication reported a complete and durable remission in a patient with
metastatic, treatment-refractory testicular cancer. This patient, who had progressed on multiple prior therapies including chemotherapy, autologous stem cell transplant, and checkpoint blockade
<FONT STYLE="white-space:nowrap">(anti&#8211;PD-1,</FONT> <FONT STYLE="white-space:nowrap">anti&#8211;CTLA-4,</FONT> anti&#8211;TIGIT), received a single infusion of <FONT STYLE="white-space:nowrap">agenT-797</FONT> with nivolumab. The patient
achieved complete clinical, radiographic, and biochemical remission, with no evidence of disease more than two years later. Donor iNKT cells were detected in circulation for up to six months, and the regimen was well tolerated. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these findings, a clinical trial (NCT06251973) is actively enrolling patients with
previously treated gastric, esophageal, or gastroesophageal junction (GEJ) adenocarcinoma. This investigator-sponsored study, led by Dr.&nbsp;Yelena Janjigian at Memorial Sloan Kettering Cancer Center, is evaluating
<FONT STYLE="white-space:nowrap">agenT-797</FONT> in combination with botensilimab (a novel <FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> <FONT STYLE="white-space:nowrap">CTLA-4</FONT> inhibitor), balstilimab
<FONT STYLE="white-space:nowrap">(anti&#8211;PD-1),</FONT> ramucirumab, and paclitaxel. The study, which aims to enroll approximately 38 patients, was highlighted at the ASCO GI Symposium in January&nbsp;2025 followed by a presentation of the immune
modulating and clinical activity of the combination at the inaugural <FONT STYLE="white-space:nowrap">AACR-IO</FONT> congress in February of 2025 and additional data are anticipated in the impending months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond oncology, <FONT STYLE="white-space:nowrap">agenT-797</FONT> has shown promise in acute pulmonary immune failure. In a clinical trial
(NCT04582201) evaluating patients with moderate to severe viral acute respiratory distress syndrome (ARDS), <FONT STYLE="white-space:nowrap">agenT-797</FONT> was associated with overall survival exceeding 70%. In the subgroup of patients receiving
veno-venous extracorporeal membrane oxygenation (VV ECMO), survival was 80%&#8212;compared to a historical ICU control survival rate of approximately 10%. These results were published in <I>Nature Communications</I> in February&nbsp;2024. Additional
clinical and translational findings from this program were presented at the American Thoracic Society (ATS) Annual Meetings in 2023 and 2024. We intend to advance development of <FONT STYLE="white-space:nowrap">agenT-797</FONT> for viral ARDS in a
large-scale, externally funded platform trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel, we are developing a pipeline of next-generation, engineered iNKT cell
therapies designed to enhance tumor targeting, overcome resistance, and remodel the tumor microenvironment. Our two most advanced preclinical candidates are <FONT STYLE="white-space:nowrap">MiNK-413,</FONT> an
<FONT STYLE="white-space:nowrap">IL-15</FONT> armored <FONT STYLE="white-space:nowrap">CAR-iNKT</FONT> targeting B cell maturation antigen (BCMA), and <FONT STYLE="white-space:nowrap">MiNK-215,</FONT> an <FONT STYLE="white-space:nowrap">IL-15</FONT>
armored <FONT STYLE="white-space:nowrap">CAR-iNKT</FONT> targeting fibroblast activation protein (FAP). Both programs have shown robust preclinical activity and competitive manufacturing advantages. <FONT STYLE="white-space:nowrap">MiNK-413</FONT>
has demonstrated tumor clearance and improved persistence in preclinical models of hematologic malignancy. <FONT STYLE="white-space:nowrap">MiNK-215</FONT> has shown potent activity in lung and colorectal cancer models, including organoid systems
with liver metastases, where it enhanced T cell-mediated killing, depleted suppressive <FONT STYLE="white-space:nowrap">FAP-expressing</FONT> stromal cells, and improved CD8+ infiltration. Preclinical data were presented at the American Society of
Gene and Cell Therapy (ASGCT) 2023 and American Association for Cancer Research (AACR) 2024 annual meetings. <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">MiNK-215</FONT> are underway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have treated nearly 100 patients across cancer and immune-mediated indications. Our work has yielded insights into the mechanisms
driving iNKT cell activity, durability, and safety. With our vertically integrated platform, proprietary technologies, and experienced leadership team, we believe we are well positioned to deliver transformative cellular immunotherapies that can be
broadly deployed across high-burden diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as AgenTus Biosciences Inc. in Delaware in July 2017. We changed our name to AgenTus Therapeutics, Inc. in October 2017
and to MiNK Therapeutics, Inc. in June 2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY 10010, and our telephone number is
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-994-8250.</FONT></FONT> Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will
contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading &#8220;Risk Factors&#8221;
in the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks,
uncertainties and assumptions discussed under the heading &#8220;Risk Factors&#8221; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
and other documents that we file with the SEC, which are incorporated herein by reference as described in this prospectus under the heading &#8220;Where You Can Find More Information&#8221;. The risks and uncertainties we have described in such
documents are not the only risks that we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_4"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference herein, and any prospectus supplement and the documents incorporated therein,
contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy and plans and our
objectives for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;expect&#8221; and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and
financial trends that we believe may affect our financial condition, results of operations, business strategy, short- and long-term business operations and objectives and financial needs. Examples of forward-looking statements include, among others,
statements we make regarding: our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, our prospects for initiating partnerships or collaborations, the timing of the
introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans, objectives, expectations, and intentions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place significant
reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that could cause actual results and
events to differ materially from those indicated in the forward-looking statements include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, process and results of our research and development programs, preclinical studies and
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate, and the timing of, preclinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> <I>in vivo</I> for multiple programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance any product candidates that we may develop and successfully complete clinical trials and
obtain licensure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to quickly leverage our initial programs and to progress additional programs to create a clinical
portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our strategic plans for our business, programs, product candidates and technology;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and technology; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments related to our competitors and our industry; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our collaborative relationship with Agenus Inc., as well as our ability to identify and
enter into future license agreements and collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key scientific and management personnel; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of our expenses, capital requirements and needs for additional financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking
statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by
applicable law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, any prospectus supplement and the documents that we
incorporate by reference herein and therein completely and with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the applicable prospectus supplement relating to a specific offering, we intend to use the net proceeds from
the sale of securities by us under this prospectus for working capital and other general corporate purposes. General corporate purposes may include, without limitation, research and development expenditures, preclinical and clinical development and
commercialization of our product candidates, the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of products or product candidates, business or technologies, collaborations, working capital and capital expenditures. We may
temporarily invest the net proceeds we receive in short-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government and its agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will have broad
discretion in the application of the net proceeds we may receive, and investors will be relying on the judgment of our management regarding the application of our net proceeds. Additional information on the use of net proceeds from the sale of
securities by us under this prospectus may be set forth in the prospectus supplement relating to the specific offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_6"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Plan of Distribution </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the
securities, from time to time, to or through underwriters or dealers, through agents or remarketing firms, or directly to one or more purchasers pursuant to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">underwritten public offerings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;at the market offerings,&#8221; within the meaning of Rule 415(a)(4) of the Securities Act of 1933, as
amended, or the Securities Act, into an existing trading market, at prevailing market prices; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of these methods. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities to or through one or more underwriters or dealers (acting as principal or agent), through agents, or directly to
one or more purchasers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the
terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of the underwriters, dealers or agents, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are to be offered through the selling efforts of brokers or dealers, the plan of distribution
and the terms of any agreement, arrangement, or understanding entered into with broker(s) or dealer(s) prior to the effective date of the registration statement, and, if known, the identity of any broker(s) or dealer(s) who will participate in the
offering and the amount to be offered through each; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive
from the sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if any of the securities being registered are to be offered otherwise than for cash, the general purposes of the
distribution, the basis upon which the securities are to be offered, the amount of compensation and other expenses of distribution, and by whom they are to be borne; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delayed delivery arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment or other options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#8217; or underwriters&#8217;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts, commissions or concessions allowed or reallowed or paid to dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity and relationships of any finders, if applicable; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Unless otherwise indicated in the prospectus supplement, subject to
certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may change from time to time. We may use underwriters, dealers or agents with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, dealer or agent, the
nature of any such relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may use a remarketing firm to offer the securities in connection with a remarketing arrangement upon
their purchase. Remarketing firms would act as principals for their own account or as agents for us. These remarketing firms would offer or sell the securities pursuant to the terms of the securities. A prospectus supplement will identify any
remarketing firm and the terms of its agreement, if any, with us and would describe the remarketing firm&#8217;s compensation. Remarketing firms may be deemed to be underwriters in connection the securities they remarket. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer and sell securities through a dealer, we or an underwriter will sell the securities to the dealer, as principal. The dealer may
then resell the securities to the public at varying prices to be determined by the dealer at the time of resale. The name of the dealer and the terms of the transaction would be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of
securities and we will describe any commissions payable to the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, the agent will act on a best-efforts basis for the period of its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dealers and agents participating in the distribution of the securities may be deemed to be underwriters, and compensation received by them on
resale of the securities may be deemed to be underwriting discounts. If such dealers or agents were deemed to be underwriters, they may be subject to statutory liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly to one or more purchasers without using underwriters or agents. Underwriters, dealers and agents that
participate in the distribution of the securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive from us and any profit on their resale of the securities may be treated as underwriting discounts
and commissions under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide
agents, underwriters and dealers with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents, underwriters or dealers may make with respect to these
liabilities. Agents, underwriters and dealers, or their respective affiliates, may engage in transactions with, or perform services for, us in the ordinary course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any securities we offer may be new issues of securities and may have no established trading
market. The securities may or may not be listed on a securities exchange. Underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We can make no
assurance as to the liquidity of, or the existence of trading markets for, any of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in
over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation M under the Exchange Act of 1934, as amended, or the Exchange Act. Over-allotment involves sales in excess of the offering size,
which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve
purchases of the securities, either through exercise of the over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer
when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the
underwriters may discontinue any of the activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters that are qualified market makers on the Nasdaq Capital
Market may engage in passive market making transactions in the common stock on the Nasdaq Capital Market in accordance with Regulation M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of
offers or sales of the common stock. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of
the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded. Passive
market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_7"></A>GENERAL DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer and sell, at any time and from time to time, subject to applicable law: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">common stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warrants to purchase our common stock, preferred stock or debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debt securities consisting of debentures, notes or other evidences of indebtedness; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">units consisting of a combination of the foregoing securities; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any combination of these securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that are exchangeable for or convertible into common stock or any of the other securities that may be sold under
this prospectus. When particular securities are offered, a supplement to this prospectus will be filed with the SEC, which will describe the terms of the offering and sale of the offered securities. If the information contained in the prospectus
supplement differs from the following description, you should rely on the information in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever references
are made in this prospectus to information that will be included in a prospectus supplement, to the extent permitted by applicable law, rules or regulations, we may instead include such information or add, update or change the information contained
in this prospectus by means of a post-effective amendment to the registration statement of which this prospectus is a part, through filings we make with the SEC that are incorporated by reference in this prospectus or by any other method as may be
permitted under applicable law, rules or regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_8"></A>DESCRIPTION OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our common stock and certain provisions of our amended and restated certificate of incorporation, or the Amended
and Restated Certificate of Incorporation, and amended and restated <FONT STYLE="white-space:nowrap">by-laws,</FONT> or the Amended and Restated Bylaws are summaries and are qualified by reference to the Amended and Restated Certificate of
Incorporation and the Amended and Restated Bylaws, copies of which are on file with the SEC as exhibits to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024. Please refer to &#8220;Where
You Can Find More Information&#8221; below for directions on obtaining these documents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.00001 per share. As of September&nbsp;30, 2025, we
had 4,600,580 shares of common stock outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters
submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. Holders of common
stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation or dissolution, the holders of common stock are entitled to receive proportionately our net assets available
for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of common stock have no preemptive, subscription, redemption or conversion rights. Our
outstanding shares of common stock are validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series
of preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Our Certificate of Incorporation and Our <FONT
STYLE="white-space:nowrap">By-laws</FONT></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended and Restated Certificate of Incorporation and Amended and Restated <FONT
STYLE="white-space:nowrap">By-Laws</FONT> contain certain provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors but which may have the effect of delaying, deferring or
preventing a future takeover or change in control of us unless such takeover or change in control is approved by our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions include: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Classified board. </I>The Amended and Restated Certificate of Incorporation provides that the board of directors is divided into three
classes of directors, with the classes as nearly equal in number as possible. As a result, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of the board of directors is elected each year. The classification of directors will have the
effect of making it more difficult for stockholders to change the composition of the board. The Amended and Restated Certificate of Incorporation also provides that, subject to any rights of holders of preferred stock to elect additional directors
under specified circumstances, the number of directors will be fixed exclusively pursuant to a resolution adopted by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Action by written consent; special meetings of stockholders.</I> The Amended and Restated Certificate of Incorporation provides that
stockholder action can be taken only at an annual or special meeting of stockholders and cannot be taken by written consent in lieu of a meeting. The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws also provide
that, except as otherwise required by law, special meetings of the stockholders can only be called pursuant to a resolution adopted by a majority of the board of directors. Except as described above, stockholders are not be permitted to call a
special meeting or to require the board of directors to call a special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Advance notice procedures. </I>The Amended and Restated Bylaws establish an advance
notice procedure for stockholder proposals to be brought before an annual meeting of the stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting are only able to consider
proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to
vote at the meeting and who has given the Secretary of the Company timely written notice, in proper form, of the stockholder&#8217;s intention to bring that business before the meeting. Although the Amended and Restated Bylaws do not give the board
of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, the Amended and Restated Bylaws may have the effect of precluding the conduct
of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Supermajority approval requirements. </I>The Delaware General Corporation Law, or the DGCL, generally provides that the
affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws,</FONT> unless either a corporation&#8217;s certificate
of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> requires a greater percentage. The Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that the affirmative vote of holders of at least 75% of
the total votes eligible to be cast in the election of directors is required to amend, alter, change or repeal specified provisions. This requirement of a supermajority vote to approve amendments to the Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws could enable a minority of the Company&#8217;s stockholders to exercise veto power over any such amendments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized but unissued shares. </I>The Company&#8217;s authorized but unissued shares of common stock and preferred stock will be
available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital, corporate acquisitions and employee benefit
plans. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of the common stock by means of a proxy contest, tender offer, merger or
otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exclusive forum. </I>Our Amended and Restated Certificate of Incorporation requires, to the fullest extent permitted by
law, that derivative actions brought in the name of the Company, actions against directors, officers and employees for breach of a fiduciary duty and other similar actions may be brought only in specified courts in the State of Delaware. Under our
Amended and Restated Certificate of Incorporation, this exclusive forum provision will not apply to claims that are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the
Court of Chancery of the State of Delaware does not have subject matter jurisdiction and explicitly does not apply to actions arising under federal securities laws, including suits brought to enforce any liability or duty created by the Securities
Act, Exchange Act, or the rules and regulations thereunder. Furthermore, our Amended and Restated Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the
United States shall be the exclusive forum for the resolution of any compliant asserting a cause of action arising under the Securities Act. Although we believe these provisions benefit us by providing increased consistency in the application of
Delaware law in the types of lawsuits to which it applies, these provisions may have the effect of discouraging lawsuits against our directors and officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;203 of the DGCL </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a
three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates
and associates, owns, or did own within three years prior to the determination of interested stockholder status, 15% or more of the corporation&#8217;s voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of
the following conditions: before the stockholder became interested, the corporation&#8217;s board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; upon
consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding
for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or at or after the time the stockholder became interested, the business combination
was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which
is not owned by the interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may &#8220;opt out&#8221; of these provisions with an express
provision in its original certificate of incorporation or an express provision in its certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> resulting from a stockholders&#8217; amendment approved by at least a majority of
the outstanding voting shares. The Company has not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of the Company may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_9"></A>DESCRIPTION OF OUR PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of our Amended and Restated Certificate of Incorporation, our board of directors is authorized to issue up to 5,000,000 shares
of our preferred stock, par value $0.00001 per share, in one or more series without stockholder approval. As of September&nbsp;30, 2025, we had no shares of preferred stock outstanding. Our board of directors has the discretion to determine the
rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our board of directors to
issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions,
future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the
prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the SEC. To the extent appropriate, this description will include, where applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares offered, the liquidation preference per share and the purchase price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price
(or how it will be calculated) and conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of any depositaries, execution or paying agents, transfer agents, registrars or other agents;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon liquidation,
dissolution or winding up of the affairs of the Company; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material limitations on issuance of any class or series of preferred stock ranking senior to or on a parity
with the series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of the Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock offered by this prospectus, when issued, will not have, or be subject to, any preemptive or similar rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_10"></A>DESCRIPTION OF OUR WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to purchase our common stock, preferred stock or debt securities in one or more series together with other securities or
separately, as described in each applicable prospectus supplement and subject to applicable law. Below is a description of certain general terms and provisions of the warrants that we may offer. Particular terms of the warrants will be described in
the applicable warrant agreements and the applicable prospectus supplement for the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will
contain, where applicable, the following terms of and other information relating to the warrants: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation and aggregate number of, and the price at which we will issue, the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currency units in which the offering price, if any, and the exercise price are payable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, amount and terms of the securities purchasable upon exercise of the warrants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for our common stock and the number of common stock to be received upon
exercise of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for our preferred stock, the number of preferred stock to be received upon
exercise of the warrants, and a description of that series of our preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the exercise price for our debt securities, the amount of our debt securities to be received upon
exercise of the warrants, and a description of that series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will begin and the date on which that right will expire or,
if the warrants may not be continuously exercised throughout that period, the specific date or dates on which the warrants may be exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants will be issued in fully registered form or bearer form, in definitive or global form or in
any combination of these forms, although, in any case, the form of a warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable material U.S. federal income tax consequences; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the warrant agent for the warrants, if any, and of any other depositaries, execution or paying
agents, transfer agents, registrars or other agents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any
securities exchange or market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date from and after which the warrants and the common stock, preferred stock or debt
securities will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anti-dilution provisions of the warrants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any redemption or call provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the warrants are to be sold separately or with other securities as parts of units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange and
exercise of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for any warrants will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_11"></A>DESCRIPTION OF OUR DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This section describes the general terms and provisions of the debt securities that we may offer under this prospectus, any of which may be
issued as convertible or exchangeable debt securities. We will set forth the particular terms of the debt securities we offer in a prospectus supplement. The extent, if any, to which the following general provisions apply to particular debt
securities will be described in the applicable prospectus supplement. The following description of general terms relating to the debt securities and the indenture under which the debt securities will be issued are summaries only and therefore are
not complete. You should read the indenture and the prospectus supplement regarding any particular issuance of debt securities. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will issue any debt under an indenture to be entered into between us and the trustee identified in the applicable prospectus supplement. The terms of the debt securities will include those stated in the indenture and those made part of the indenture
by reference to the Trust Indenture Act of 1939, as in effect on the date of the indenture. We have filed or will file a copy of the form of indenture as an exhibit to the registration statement in which this prospectus is included. The indenture
will be subject to and governed by the terms of the Trust Indenture Act of 1939. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer under this prospectus up to an aggregate
principal amount of $150,000,000 in debt securities, or if debt securities are issued at a discount, or in a foreign currency, foreign currency units or composite currency, the principal amount as may be sold for an aggregate initial public offering
price of up to $150,000,000. Unless otherwise specified in the applicable prospectus supplement, the debt securities will represent direct, unsecured obligations of the Company and will rank equally with all of our other unsecured indebtedness. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following statements relating to the debt securities and the indenture are summaries, qualified in their entirety by reference to the
detailed provisions of the indenture and the final form indenture as may be filed with a future prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities in one or more series with the same or various maturities, at par, at a premium, or at a discount. We will
describe the particular terms of each series of debt securities in a prospectus supplement relating to that series, which we will file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will set forth, to the extent required, the following terms of the debt securities in respect of which the
prospectus supplement is delivered: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issue price or prices, expressed as a percentage of the aggregate principal amount of the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which principal is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates (which may be fixed or variable) or, if applicable, the method used to determine such
rate or rates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates from which interest, if any, will be payable and any regular record date for the interest
payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal and, if applicable, premium and interest, is payable; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions upon which we may, or the holders may require us to, redeem or repurchase the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which such debt securities may be issuable, if other than denominations of $1,000 or any
integral multiple of that number; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities are to be issuable in the form of certificated securities (as described below) or
global securities (as described below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount that will be payable upon declaration of acceleration of the maturity date if
other than the principal amount of the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal and, if applicable,
premium and interest, will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal and, if applicable, premium or interest, on the debt securities are to be made in one or
more currencies or currency units other than the currency of denomination, the manner in which the exchange rate with respect to such payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if amounts of principal and, if applicable, premium and interest may be determined by reference to an index based
on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index, then the manner in which such amounts will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to any collateral provided for such debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to or change in the covenants or the acceleration provisions described in this prospectus or in the
indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any events of default, if not otherwise described below under &#8220;Events of Default&#8221;;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, for conversion into or exchange for our common stock or preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which the debt securities shall be subordinated in right of payment to
other indebtedness of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue discount debt securities that provide for an amount less than the
stated principal amount to be due and payable upon acceleration of the maturity of such debt securities in accordance with the terms of the indenture. We may also issue debt securities in bearer form, with or without coupons. If we issue discount
debt securities or debt securities in bearer form, we will describe material U.S. federal income tax considerations and other material special considerations which apply to these debt securities in the applicable prospectus supplement. We may issue
debt securities denominated in or payable in a foreign currency or currencies or a foreign currency unit or units. If we do, we will describe the restrictions, elections, and general tax considerations relating to the debt securities and the foreign
currency or currencies or foreign currency unit or units in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that will be represented by either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;book-entry securities,&#8221; which means that there will be one or more global securities registered in
the name of a depositary or a nominee of a depositary; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#8220;certificated securities,&#8221; which means that they will be represented by a certificate issued in
definitive registered form. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will specify in the prospectus supplement applicable to a particular offering whether the
debt securities offered will be book-entry or certificated securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange and Conversion Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities which can be exchanged for or converted into our common stock or preferred stock, subject to applicable law. If we
do, we will describe the terms of exchange or conversion in the prospectus supplement relating to these debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certificated Debt Securities
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold certificated debt securities issued under an indenture, you may transfer or exchange such debt securities in accordance
with the terms of the indenture. You will not be charged a service charge for any transfer or exchange of certificated debt securities but may be required to pay an amount sufficient to cover any tax or other governmental charge payable in
connection with such transfer or exchange. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of a series may be issued in the form of one or more global securities that will be deposited with a depositary or its
nominees identified in the prospectus supplement relating to the debt securities. In such a case, one or more global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal amount of
outstanding debt securities of the series to be represented by such global security or securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until it is exchanged in
whole or in part for debt securities in definitive registered form, a global security may not be registered for transfer or exchange except as a whole by the depositary for such global security to a nominee of the depositary and except in the
circumstances described in the prospectus supplement relating to the debt securities. The specific terms of the depositary arrangement with respect to a series of debt securities will be described in the prospectus supplement relating to such
series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Protection in the Event of Change of Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision in an indenture that governs our debt securities covered by this prospectus that includes any covenant or other provision
providing for a put or increased interest or otherwise that would afford holders of our debt securities additional protection in the event of a recapitalization transaction, a change of control of the Company, or a highly leveraged transaction will
be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in this prospectus or the applicable prospectus supplement, our debt securities may not have the benefit of any
covenant that limits or restricts our business or operations, the pledging of our assets or the incurrence by us of indebtedness. We will describe in the applicable prospectus supplement any material covenants in respect of a series of debt
securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may agree in any indenture that governs the debt securities of any series covered by this prospectus that we will not consolidate with or
merge into any other person or convey, transfer, sell or lease our properties and assets substantially as an entirety to any person, unless such person and such proposed transaction meets various criteria, which we will describe in detail in the
applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defaults and Notice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of any series will contain events of default to be specified in the applicable prospectus supplement, which may include,
without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to pay the principal of, or premium or make-whole amount, if any, on any debt security of such series
when due and payable (whether at maturity, by call for redemption, through any mandatory sinking fund, by redemption at the option of the holder, by declaration or acceleration or otherwise); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to make a payment of any interest on any debt security of such series when due; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to perform or observe any other covenants or agreements in the indenture with respect to the debt
securities of such series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain events relating to our bankruptcy, insolvency or reorganization; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain cross defaults, if and as applicable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series shall occur and be continuing, we may agree that the trustee or the
holders of at least 25% in aggregate principal amount of the then outstanding debt securities of such series may declare the principal amount (or, if the debt securities of such series are issued at an original issue discount, such portion of the
principal amount as may be specified in the terms of the debt securities of such series) of all debt securities of such series or such other amount or amounts as the debt securities or supplemental indenture with respect to such series may provide,
to be due and payable immediately. Any provisions pertaining to events of default and any remedies associated therewith will be described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus may require that the trustee under such indenture shall, within 90
days after the occurrence of a default, give to holders of debt securities of any series notice of all uncured defaults with respect to such series known to it. However, except in the case of a default that results from the failure to make any
payment of the principal of, premium, if any, or interest on the debt securities of any series, or in the payment of any mandatory sinking fund installment with respect to debt securities of such series, if any, the trustee may withhold such notice
if it in good faith determines that the withholding of such notice is in the interest of the holders of debt securities of such series. Any terms and provisions relating to the foregoing types of provisions will be described in further detail in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus will contain a provision
entitling the trustee to be indemnified by holders of debt securities before proceeding to exercise any trust or power under the indenture at the request of such holders. Any such indenture may provide that the holders of at least a majority in
aggregate principal amount of the then outstanding debt securities of any series may direct the time, method and place of conducting any proceedings for any remedy available to the trustee, or of exercising any trust or power conferred upon the
trustee with respect to the debt securities of such series. However, the trustee under any such indenture may decline to follow any such direction if, among other reasons, the trustee determines in good faith that the actions or proceedings as
directed may not lawfully be taken, would involve the trustee in personal liability or would be unduly prejudicial to the holders of the debt securities of such series not joining in such direction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any indenture that governs our debt securities covered by this prospectus may endow the holders of such debt securities to institute a
proceeding with respect to such indenture, subject to certain conditions, which will be specified in the applicable prospectus supplement and which may include, that the holders of at least a majority in aggregate principal amount of the debt
securities of such series then outstanding make a written request upon the trustee to exercise its power under the indenture, indemnify the trustee and afford the trustee reasonable opportunity to act. Even so, such holders may have an absolute
right to receipt of the principal of, premium or make-whole amount, if any, and interest when due, to require conversion or exchange of debt </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities if such indenture provides for convertibility or exchangeability at the option of the holder and to institute suit for the enforcement of such rights. Any terms and provisions relating
to the foregoing types of provisions will be described in further detail in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may modify any indenture that governs our debt securities of any series covered by this prospectus with or without
the consent of the holders of such debt securities, under certain circumstances to be described in a prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance; Satisfaction
and Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement will outline the conditions under which we may elect to have certain of our obligations under
the indenture discharged and under which the indenture obligations will be deemed to be satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will identify the trustee and any relationship that we may have with such trustee, with respect to any series of debt securities, in the
prospectus supplement relating to the applicable debt securities. You should note that if the trustee becomes a creditor of the Company, the indenture and the Trust Indenture Act of 1939 limit the rights of the trustee to obtain payment of claims in
certain cases, or to realize on certain property received in respect of any such claim, as security or otherwise. The trustee and its affiliates may engage in, and will be permitted to continue to engage in, other transactions with us and our
affiliates. If, however, the trustee acquires any &#8220;conflicting interest&#8221; within the meaning of the Trust Indenture Act of 1939, it must eliminate such conflict or resign. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The law governing the
indenture and the debt securities will be identified in the prospectus supplement relating to the applicable indenture and debt securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_12"></A>DESCRIPTION OF OUR UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the
material terms and provisions of the units that we may offer under this prospectus. Units may be offered independently or together with common stock, preferred stock, debt securities or warrants offered by any prospectus supplement, and may be
attached to or separate from those securities. While the terms we have summarized below will generally apply to any future units that we may offer under this prospectus, we will describe the particular terms of any series of units that we may offer
in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of unit agreement, including a
form of unit certificate, if any, that describes the terms of the series of units we are offering before the issuance of the related series of units. The following summaries of material provisions of the units, and the unit agreements, are subject
to, and qualified in their entirety by reference to, all the provisions of the unit agreement applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the units that we sell under this
prospectus, as well as the complete unit agreements that contain the terms of the units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more common stock, preferred stock, debt securities and warrants in any combination. Each unit will be
issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued
may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of units, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether, and under
what circumstances, those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rights and obligations of the unit agent, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement that differ from those described below; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#8220;Description of
Our Common Stock,&#8221; &#8220;Description of Our Preferred Stock,&#8221; &#8220;Description of Our Debt Securities&#8221; and &#8220;Description of Our Warrants,&#8221; will apply to each unit and to any common stock, preferred stock, debt
securities or warrants included in each unit, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in such amounts and in numerous distinct series as we determine. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site at
http://www.sec.gov that contains the reports, statements and other information about issuers, such as us, who file electronically with the SEC. We also maintain a website at www.minktherapeutics.com, at which you may access these materials free of
charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessible through our website is not a part of this prospectus or any prospectus supplement, and the inclusion
of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#8220;incorporate by
reference&#8221; into this prospectus the information in other documents that we file with it. This means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered
to be a part of this prospectus, and information in documents that we file later with the SEC will automatically update and supersede information contained in documents filed earlier with the SEC or contained in this prospectus. We incorporate by
reference in this prospectus (i)&nbsp;the documents listed below, (ii)&nbsp;all documents that we file with the SEC under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the registration statement
of which this prospectus is included and prior to the effectiveness of such registration statement, and (iii)&nbsp;and any future filings that we may make with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the
termination of the offering under this prospectus; <I>provided</I>,<I> however</I>,<I> </I>that we are not incorporating, in each case, any documents or information deemed to have been furnished and not filed, including any information that we
disclose under Items 2.02 or 7.01 of any Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> in accordance with SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025041379/inkt-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;18, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended
March&nbsp;31, 2025 and June&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025072789/inkt-20250331.htm">May&nbsp;
15, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025108894/inkt-20250630.htm">August&nbsp;14, 2025</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000119312525009595/d926991d8k.htm">January&nbsp;21,
 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025087888/inkt-20250618.htm">June&nbsp;
18, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001840229/000095017025095460/inkt-20250711.htm">July&nbsp;
14, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001840229/000119312525159017/d99462d8k.htm">July&nbsp;
15, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001840229/000119312525221863/inkt-20250923.htm">September&nbsp;29, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our annual Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017025061041/mink-def_14a_2025.htm">Schedule
 14A</A> relating to our annual meeting of stockholders, filed on April&nbsp;30, 2025 (with respect to those portions incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2024); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521297781/d232393d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40908)</FONT> filed with the SEC on October&nbsp;13, 2021, including any amendment or report filed for the purpose of updating such
description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon request, either orally or in writing, we will provide, without charge, to each person, including any
beneficial owner, to whom a copy of this prospectus is delivered, a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings and any exhibits we have
specifically incorporated by reference as an exhibit in this prospectus, at no cost, by writing to us at the following address: MiNK Therapeutics, Inc., 149 Fifth Avenue, Suite 500, New York, New York 10010; Attention: Investor Relations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_14"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement indicates otherwise, the validity of any securities offered from time to time by this prospectus
will be passed upon for us by Latham&nbsp;&amp; Watkins LLP. The validity of any securities will be passed upon for any underwriters or agents by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca62147_15"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of MiNK Therapeutics, Inc. as of December&nbsp;31, 2024 and 2023 and for the years then ended, have been
incorporated by reference herein and in the Registration Statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting
and auditing. The audit report covering the December&nbsp;31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has a net capital deficiency that
raises substantial doubt about the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g62147g04x33.jpg" ALT="LOGO" STYLE="width:3.03472in;height:0.972222in;">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Units
</B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>, 2025 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#ff4338"><B>The information contained in this prospectus supplement is not complete and may be changed. We may not sell these securities until the
registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where such offer or
sale is not permitted. </B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);"> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>SUBJECT TO COMPLETION, DATED NOVEMBER&nbsp;7, 2025 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>(To Prospectus
dated&#8195;&#8195;&#8195;&#8195;) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g62147g34x50.jpg" ALT="LOGO" STYLE="width:2.81482in;height:0.894618in;">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Up to $50,000,000 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">This prospectus supplement relates to the issuance and sale of up to $50,000,000 of our common stock, $0.00001 par value per share, from time to
time through our sales agent, B. Riley Securities, Inc. (the &#8220;Sales Agent&#8221;). We have entered into an At Market Issuance Sales Agreement (the &#8220;ATM Sales Agreement&#8221;) with the Sales Agent relating to shares of our common stock
offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the ATM Sales Agreement, we may offer and sell shares up to $50,000,000 of our common stock from time to time through the Sales Agent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">We are subject to the offering limits in General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> As of November&nbsp;6,
2025, the aggregate market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or public float, calculated for purposes of General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> is
$35,031,699, which was calculated based on 2,149,184 shares of our outstanding common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of such date and a price of $16.30&nbsp;per share, the closing price of our common stock on
September&nbsp;22, 2025, which is the highest closing sale price of our common stock on the Nasdaq Capital Market within the prior 60 days. During the prior 12 calendar month period that ends on and includes the date of this prospectus supplement,
we have offered and sold 163,660 shares of common stock for gross proceeds of $5,035,949 pursuant to General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Pursuant to General Instruction I.B.6 of Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> in no event will we sell securities in public primary offerings on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with a value exceeding <FONT STYLE="white-space:nowrap">one-third</FONT> of our public float
(as defined by General Instruction I.B.6) in any <FONT STYLE="white-space:nowrap">12-calendar</FONT> month period so long as our public float remains below $75.0&nbsp;million. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">As a result of the limitations on the maximum amount of shares that we are eligible to offer and sell under General Instruction I.B.6 of Form <FONT
STYLE="white-space:nowrap">S-3,</FONT> we may currently only offer and sell shares of our common stock having an aggregate offering price of up to $6,641,284 pursuant to the ATM Sales Agreement. However, in the event that our public float increases
or decreases, we may sell securities in public primary offerings on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with a value up to <FONT STYLE="white-space:nowrap">one-third</FONT> of our public float in any
<FONT STYLE="white-space:nowrap">12-calendar</FONT> month period, in each case calculated pursuant to General Instruction I.B.6 and subject to the terms of the ATM Sales Agreement. In the event that our public float increases above
$75.0&nbsp;million, we will no longer be subject to the limits in General Instruction I.B.6 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;INKT.&#8221; On November&nbsp;6, 2025, the last reported sale
price of the common stock on the Nasdaq Capital Market was $13.66 per share. You are urged to obtain current market quotations for our common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Shares of our common stock covered by this prospectus supplement and the accompanying prospectus may be sold by any method deemed to be an
&#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). When it receives a sale order from us, the Sales Agent has agreed to use its commercially reasonable
efforts to execute on the order on mutually agreed terms. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">The compensation payable to the Sales Agent for sales of common stock sold pursuant to the ATM Sales Agreement will be an aggregate of 3.0% of
the gross proceeds of the sales price of common stock sold. We anticipate no other commissions or material expenses for sales under the ATM Sales Agreement. The orders will be executed at price limits imposed by us. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Even though this prospectus supplement does not relate to a marketed offering of our common stock, in connection with the sale of common stock
under the ATM Sales Agreement, the Sales Agent will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of the Sales Agent will be deemed to be underwriting commissions or discounts. We have
agreed to indemnify the Sales Agent against certain civil liabilities, including liabilities under the Securities Act. See the section titled &#8220;Plan of Distribution&#8221; on <FONT STYLE="white-space:nowrap">page&nbsp;S-9</FONT> of this
prospectus supplement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>You should read carefully and consider the &#8220;<A HREF="#txb62147_4">Risk Factors</A>&#8221; referenced on page <FONT
STYLE="white-space:nowrap">S-5</FONT> of this prospectus supplement and the risk factors described in other documents incorporated by reference herein. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Sales Agent </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><B>B. RILEY SECURITIES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is&#8195;&#8195;&#8195;&#8195;. </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P></DIV> <p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_1">ABOUT THIS PROSPECTUS SUPPLEMENT </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_5">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#txb62147_11">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus are a part of a registration statement that we filed with the Securities and
Exchange Commission (the &#8220;SEC&#8221;) utilizing a &#8220;shelf&#8221; registration process. Under the shelf registration process, we may offer shares of our common stock from time to time under this prospectus supplement and the accompanying
prospectus at prices and on terms to be determined by market conditions at the time of offering. This prospectus supplement, the accompanying prospectus and the documents incorporated herein and therein by reference include important information
about us, the shares being offered and other information you should know before investing in our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on
this prospectus supplement, the accompanying prospectus and the information incorporated or deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and the Sales Agent has not, authorized
anyone to provide you with information that is in addition to or different from that contained or incorporated by reference in this prospectus. We are not, and the Sales Agent is not, offering to sell these securities in any jurisdiction where the
offer or sale is not permitted. You should not assume that the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate as of any date other than as of the date of this prospectus
supplement and the accompanying prospectus or in the case of the documents incorporated by reference, the date of such documents regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or any sale of our
common stock. Our business, financial condition, liquidity, results of operations and prospects may have changed since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As
used in this prospectus supplement, unless the context otherwise requires, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; and &#8220;MiNK&#8221; mean, collectively, MiNK Therapeutics, Inc. and its
subsidiaries and their predecessors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement also includes trademarks, tradenames and service marks that are the
property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus supplement appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not
assert its rights, to these trademarks and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information about us, this offering and information appearing elsewhere in this prospectus supplement, in
the accompanying prospectus and in the documents we incorporate by reference. This summary is not complete and does not contain all of the information you should consider before investing in our securities. Before making an investment decision, to
fully understand this offering and its consequences to you, you should carefully read this entire prospectus supplement and the accompanying prospectus, including &#8220;Risk Factors&#8221; beginning on page
<FONT STYLE="white-space:nowrap">S-5</FONT> of this prospectus supplement and the financial statements and related notes and the other information that we incorporate by reference into this prospectus supplement. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company developing <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> invariant natural
killer T (iNKT) cell therapies designed to treat cancer and immune-mediated diseases. Our therapies are based on a proprietary platform of allogeneic, <FONT STYLE="white-space:nowrap">ex-vivo</FONT> expanded iNKT cells&#8212;cells that are designed
to uniquely combine the precision and memory of adaptive T cells with the speed and potency of natural killer (NK) cells. This rare biology is designed to allow iNKT cells to navigate tissues, eliminate tumors and infected cells, and reprogram the
immune environment&#8212;all without graft-versus-host disease (GVHD). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe iNKT cells represent an optimal platform for <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> cellular immunotherapy. Unlike conventional T or NK cell therapies, our iNKT cells can persist without lymphodepletion and function without the need for human
leukocyte antigen (HLA) matching. This allows for scalable, repeatable, and widely accessible treatment options in indications with significant unmet need. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach includes the development of both native and engineered iNKT cell therapies. Our pipeline includes wholly owned and exclusively
licensed assets targeting solid tumors, pulmonary immune failure, and immune-related disorders. We have also developed a proprietary neoantigen library that supports personalized TCR development by identifying patient-specific tumor signatures.
These insights can be used to create highly tailored <FONT STYLE="white-space:nowrap">TCR-iNKT</FONT> therapies, enabling precision targeting across cancers and complex immune pathologies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">agenT-797,</FONT> is an allogeneic, native iNKT cell therapy in development for
both oncology and immune-mediated diseases. In a clinical trial (NCT05108623) involving patients with treatment-refractory solid tumors, <FONT STYLE="white-space:nowrap">agenT-797</FONT> was evaluated as monotherapy and in combination with <FONT
STYLE="white-space:nowrap">PD-1</FONT> inhibitors nivolumab or pembrolizumab. Treatment was associated with reductions in target and <FONT STYLE="white-space:nowrap">non-target</FONT> lesions and durable disease stabilization, including a partial
response in a patient with checkpoint-refractory gastric cancer. <FONT STYLE="white-space:nowrap">AgenT-797</FONT> also demonstrated long-term persistence in the bloodstream&#8212;up to six months&#8212;without HLA matching or lymphodepletion. The
therapy was well tolerated, with no cases of cytokine release syndrome (CRS) or GVHD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data were presented at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting in 2024. Preclinical data from the same program demonstrated that <FONT STYLE="white-space:nowrap">agenT-797,</FONT> when combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, or DLL3,
enhanced tumor cell killing, T cell activation, and reduced exhaustion markers&#8212;supporting potential future combination strategies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further peer-reviewed data support the clinical activity of <FONT STYLE="white-space:nowrap">agenT-797.</FONT> A case report published in
<I>Oncogene</I> in January&nbsp;2024 described a patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival after a single infusion of
<FONT STYLE="white-space:nowrap">agenT-797</FONT> plus nivolumab. More recently, on July&nbsp;11, 2025, a landmark <I>Oncogene</I> publication reported a complete and durable remission in a patient with metastatic, treatment-refractory testicular
cancer. This patient, who had progressed on multiple prior therapies including chemotherapy, autologous stem cell transplant, and checkpoint blockade <FONT STYLE="white-space:nowrap">(anti&#8211;PD-1,</FONT>
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">anti&#8211;CTLA-4,</FONT> anti&#8211;TIGIT), received a single infusion of <FONT STYLE="white-space:nowrap">agenT-797</FONT> with nivolumab. The patient achieved
complete clinical, radiographic, and biochemical remission, with no evidence of disease more than two years later. Donor iNKT cells were detected in circulation for up to six months, and the regimen was well tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on these findings, a clinical trial (NCT06251973) is actively enrolling patients with previously treated gastric, esophageal, or
gastroesophageal junction (GEJ) adenocarcinoma. This investigator-sponsored study, led by Dr.&nbsp;Yelena Janjigian at Memorial Sloan Kettering Cancer Center, is evaluating <FONT STYLE="white-space:nowrap">agenT-797</FONT> in combination with
botensilimab (a novel <FONT STYLE="white-space:nowrap">Fc-enhanced</FONT> <FONT STYLE="white-space:nowrap">CTLA-4</FONT> inhibitor), balstilimab <FONT STYLE="white-space:nowrap">(anti&#8211;PD-1),</FONT> ramucirumab, and paclitaxel. The study, which
aims to enroll approximately 38 patients, was highlighted at the ASCO GI Symposium in January&nbsp;2025 followed by a presentation of the immune modulating and clinical activity of the combination at the inaugural
<FONT STYLE="white-space:nowrap">AACR-IO</FONT> congress in February of 2025 and additional data are anticipated in the impending months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond oncology, <FONT STYLE="white-space:nowrap">agenT-797</FONT> has shown promise in acute pulmonary immune failure. In a clinical trial
(NCT04582201) evaluating patients with moderate to severe viral acute respiratory distress syndrome (ARDS), <FONT STYLE="white-space:nowrap">agenT-797</FONT> was associated with overall survival exceeding 70%. In the subgroup of patients receiving
veno-venous extracorporeal membrane oxygenation (VV ECMO), survival was 80%&#8212;compared to a historical ICU control survival rate of approximately 10%. These results were published in <I>Nature Communications</I> in February&nbsp;2024. Additional
clinical and translational findings from this program were presented at the American Thoracic Society (ATS) Annual Meetings in 2023 and 2024. We intend to advance development of <FONT STYLE="white-space:nowrap">agenT-797</FONT> for viral ARDS in a
large-scale, externally funded platform trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel, we are developing a pipeline of next-generation, engineered iNKT cell
therapies designed to enhance tumor targeting, overcome resistance, and remodel the tumor microenvironment. Our two most advanced preclinical candidates are <FONT STYLE="white-space:nowrap">MiNK-413,</FONT> an
<FONT STYLE="white-space:nowrap">IL-15</FONT> armored <FONT STYLE="white-space:nowrap">CAR-iNKT</FONT> targeting B cell maturation antigen (BCMA), and <FONT STYLE="white-space:nowrap">MiNK-215,</FONT> an <FONT STYLE="white-space:nowrap">IL-15</FONT>
armored <FONT STYLE="white-space:nowrap">CAR-iNKT</FONT> targeting fibroblast activation protein (FAP). Both programs have shown robust preclinical activity and competitive manufacturing advantages. <FONT STYLE="white-space:nowrap">MiNK-413</FONT>
has demonstrated tumor clearance and improved persistence in preclinical models of hematologic malignancy. <FONT STYLE="white-space:nowrap">MiNK-215</FONT> has shown potent activity in lung and colorectal cancer models, including organoid systems
with liver metastases, where it enhanced T cell-mediated killing, depleted suppressive <FONT STYLE="white-space:nowrap">FAP-expressing</FONT> stromal cells, and improved CD8+ infiltration. Preclinical data were presented at the American Society of
Gene and Cell Therapy (ASGCT) 2023 and American Association for Cancer Research (AACR) 2024 annual meetings. <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">MiNK-215</FONT> are underway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have treated nearly 100 patients across cancer and immune-mediated indications. Our work has yielded insights into the mechanisms
driving iNKT cell activity, durability, and safety. With our vertically integrated platform, proprietary technologies, and experienced leadership team, we believe we are well positioned to deliver transformative cellular immunotherapies that can be
broadly deployed across high-burden diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as AgenTus Biosciences Inc. in Delaware in July&nbsp;2017. We changed our name to AgenTus Therapeutics, Inc. in
October&nbsp;2017 and to MiNK Therapeutics, Inc. in June&nbsp;2021. Our principal executive offices are located at 149 Fifth Avenue Suite 500, New York, NY 10010, and our telephone number is <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">212-994-8250.</FONT></FONT> Our website is minktherapeutics.com. Information contained on, or that can be accessed through, our website is not part of this prospectus supplement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_3"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not
contain all the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled &#8220;Description of Common Stock&#8221; in the accompanying prospectus. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="53%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock offered by us</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shares of common stock having an aggregate offering price of up to $50,000,000.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common stock outstanding after this offering</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to 7,650,600 shares, assuming sales of 3,660,322 shares of common stock in this offering at an offering price of $13.66 per share, which was the last reported price of our shares of common stock on the Nasdaq Capital Market on
November&nbsp;6, 2025. The actual number of shares issued will vary depending on how many shares we choose to sell under this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Plan of Distribution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8220;At the market offering&#8221; that may be made from time to time for our common stock in the United States through the Sales Agent. See the section entitled &#8220;Plan of Distribution&#8221; below.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Use of proceeds</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">We intend to use the net proceeds from this offering, if any, for working capital and other general corporate purposes which may include, without limitation, research and development expenditures, preclinical and clinical
development and commercialization of our product candidates, the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of products or product candidates, business or technologies, collaborations, working capital and capital
expenditures. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Risk factors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Your investment in our common stock involves substantial risks. You should consider the &#8220;Risk Factors&#8221; beginning on page <FONT STYLE="white-space:nowrap">S-5</FONT> of this prospectus supplement and incorporated by
reference in this prospectus supplement, including the risk factors incorporated by reference from our filings with the SEC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Nasdaq Capital Market Symbol</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8220;INKT&#8221;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering is based on
3,990,278 shares of our common stock outstanding as of June&nbsp;30, 2025 and excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">857,470 shares of common stock issuable upon exercise of the options granted to employees and <FONT
STYLE="white-space:nowrap">non-employees,</FONT> as well as options granted to members of the board of directors, at a weighted-average exercise price of $5.80 per share, as of June&nbsp;30, 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">80,651 shares of common stock issuable upon vesting of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock
granted to employees, consultants and directors, as of June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">399,584 shares of common stock reserved for issuance under our 2021 Equity Incentive Plan, as of June&nbsp;30,
2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">173,492 shares of common stock reserved for issuance under our 2021 Employee Stock Purchase Plan, as of
June&nbsp;30, 2025; and </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares of common stock issuable upon the conversion of our outstanding convertible promissory notes due
January&nbsp;1, 2026. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus supplement reflects and assumes no exercise of
outstanding options and warrants to purchase common stock, and no issuance of shares available for future issuance under our equity compensation plans. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Before purchasing any of the securities you should carefully consider the risk factors relating to MiNK described below and incorporated by
reference in this prospectus supplement and the accompanying prospectus from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024, our Quarterly Reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> for the quarters ended March&nbsp;31, 2025 and June&nbsp;30, 2025, as well as the risks, uncertainties and additional information set forth in our reports on Forms
<FONT STYLE="white-space:nowrap">10-K,</FONT> <FONT STYLE="white-space:nowrap">10-Q</FONT> and <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC, and in the other documents incorporated by reference into this prospectus and the
accompanying prospectus. For a description of these reports and documents, and information about where you can find them, see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Documents By Reference.&#8221;
Additional risks not presently known or that we presently consider to be immaterial could subsequently materially and adversely affect our financial condition, results of operations, business and prospects. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Risks Relating to this Offering and Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not approve. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use the net proceeds of this offering, if any, for working capital and other general corporate purposes which may
include, without limitation, research and development expenditures, preclinical and clinical development and commercialization of our product candidates, the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of products or product
candidates, business or technologies, collaborations, working capital and capital expenditures. This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and
timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from clinical trials, as well as any collaborations that we may enter into with
third parties for our product candidates, and any unforeseen cash needs. Because of the number and variability of factors that will determine our use of the proceeds from this offering, their ultimate use may vary substantially from their currently
intended use. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering and could spend the proceeds in ways that do not necessarily improve our operating results or enhance the value of our
common stock. See &#8220;Use of Proceeds.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial
dilution in the book value of your shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The public offering price of our common stock is substantially higher than the net
tangible book value per share of our common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. Assuming
the sale of 3,660,322 shares of our common stock in this offering, based on the assumed public offering price of $13.66 per share, which was the last reported sale price of our common stock on Nasdaq Capital Market on November&nbsp;6, 2025, and net
tangible book value per share of our common stock of $(6.31) as of June&nbsp;30, 2025, if you purchase shares in this offering, you will suffer immediate and substantial dilution of $(10.64) per share in the net tangible book value of common stock
purchased. To the extent shares are issued under outstanding options or warrants, you will incur further dilution. See &#8220;Dilution&#8221; for a more detailed description of the dilution to new investors in the offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to raise additional capital, we may at any time, including during the pendency of this offering, offer additional shares of our common
stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is
less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our
common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_5"></A>CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein and other written and oral
statements we make from time to time contain certain &#8220;forward-looking&#8221; statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange
Act&#8221;). You can identify these forward-looking statements by the fact they use words such as &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;may,&#8221;
&#8220;project,&#8221; &#8220;guidance,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;potential,&#8221; &#8220;opportunity,&#8221; &#8220;future&#8221; and other words and terms of similar meaning
and expression in connection with any discussion of future operating or financial performance. You can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking
statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These
statements relate to, among other things, our business strategy, our research and development, our product development efforts, our ability to commercialize our product candidates, the activities of our licensees, our prospects for initiating
partnerships or collaborations, the timing of the introduction of products, the effect of new accounting pronouncements, uncertainty regarding our future operating results and our profitability, anticipated sources of funds as well as our plans,
objectives, expectations, and intentions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have included more detailed descriptions of these risks and uncertainties and other risks
and uncertainties applicable to our business that we believe could cause actual results to differ materially from any forward-looking statement in the &#8220;Risk Factors&#8221; sections of this prospectus supplement, the accompanying prospectus and
the documents incorporated by reference herein including, but not limited to, the risk factors incorporated by reference from our filings with the SEC. We encourage you to read those descriptions carefully. Although we believe we have been prudent
in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved. We caution investors not to place significant reliance on forward-looking statements; such statements need to be
evaluated in light of all the information contained and incorporated by reference in this prospectus supplement and the accompanying prospectus. Furthermore, the statements speak only as of the date of each document, and we undertake no obligation
to update or revise these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from this offering, if any, for working capital and other general corporate purposes which may include,
without limitation, research and development expenditures, preclinical and clinical development and commercialization of our product candidates, the acquisition or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of products or product
candidates, business or technologies, collaborations, working capital and capital expenditures. We have not determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over
the allocation of net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the public offering price
per share and the <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share after this offering. We calculate net tangible book value per share by dividing the net tangible book value, which is tangible assets less total
liabilities, by the number of outstanding shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, we had a net tangible book value of
$(25.2)&nbsp;million, or $(6.31)&nbsp;per share of common stock. Our net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of common stock outstanding at June&nbsp;30, 2025, after
giving effect to the assumptions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of our common stock in the aggregate amount of
$50.0&nbsp;million at an assumed offering price of $13.66&nbsp;per share, the last reported sale price of our common stock on Nasdaq Capital Market as of November&nbsp;6, 2025, and after deducting estimated offering commissions and expenses payable
by us, our net tangible book value as of June&nbsp;30, 2025 would have been $23.1&nbsp;million, or $3.02 per share of common stock. This represents an immediate increase in the net tangible book value of $9.33 per share to our existing stockholders
and an immediate and substantial dilution in net tangible book value of $(10.64) per share to new investors. The following table illustrates this per share dilutions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of June&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6.31)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">As-Adjusted</FONT> net tangible book value per share as of
June&nbsp;30, 2025, after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10.64)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above discussion and table exclude: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">857,470 shares of common stock issuable upon exercise of the options granted to employees and <FONT
STYLE="white-space:nowrap">non-employees,</FONT> as well as options granted to members of the board of directors, at a weighted-average exercise price of $5.80 per share, as of June&nbsp;30, 2025; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">80,651 shares of common stock issuable upon vesting of <FONT STYLE="white-space:nowrap">non-vested</FONT> stock
granted to employees, consultants and directors, as of June&nbsp;30, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">399,584 shares of common stock reserved for issuance under our 2021 Equity Incentive Plan, as of June&nbsp;30,
2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">173,492 shares of common stock reserved for issuance under our 2021 Employee Stock Purchase Plan, as of
June&nbsp;30, 2025; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shares of common stock issuable upon the conversion of our outstanding promissory convertible notes due
January&nbsp;1, 2026. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent any of these outstanding options or warrants are exercised at a price less than the
public offering price, there may be further dilution to purchasers of our common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information above reflects
and assumes no exercise of outstanding options and warrants to purchase common stock, and no issuance of shares available for future issuance under our equity compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the ATM Sales Agreement we may issue and sell an aggregate of up to $50,000,000 of our common stock from time to time through the
Sales Agent. The ATM Sales Agreement has been filed with the SEC and is incorporated by reference into this prospectus. This is a brief summary of the material terms of the ATM Sales Agreement and does not purport to be a complete statement of its
terms and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time that we wish to sell common stock under the ATM Sales Agreement, we will provide the Sales Agent with a
placement notice describing the number or dollar value of shares to be issued, the time period during which sales are requested to be made, any limitation on the number of shares that may be sold in any one day and any minimum price below which
sales may not be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of a placement notice from us, and subject to the terms and conditions of the ATM Sales Agreement,
the Sales Agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations, and the rules of Nasdaq to sell such shares up to the amount
specified. The settlement between us and the Sales Agent of each sale will occur on the second trading day following the date on which the sale was made or on some other date that is agreed upon by us and the Sales Agent in connection with a
particular transaction. The obligation of the Sales Agent under the ATM Sales Agreement to sell our common stock pursuant to a placement notice is subject to a number of conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the Sales Agent a commission of up to 3.0% of the gross proceeds of the sale price per share. In addition, we have agreed to
reimburse the Sales Agent for the reasonable and documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and disbursements of its counsel incurred in connection with entering into the
transactions contemplated by the ATM sales agreement in an amount not to exceed $75,000 in the aggregate, and ongoing diligence arising from the transactions contemplated by the ATM sales agreement in an amount not to exceed $5,000 in the aggregate
per calendar quarter. We estimate that the total expenses for the offering, excluding compensation and reimbursements payable to the Sales Agent under the terms of the ATM Sales Agreement, will be approximately $200,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual proceeds to us will vary depending on the number of shares sold and the prices of such sales. Because there is no minimum offering
amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock contemplated in this prospectus, the Sales Agent will be deemed to be an
&#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation paid to the Sales Agent will be deemed to be underwriting commissions or discounts. We have agreed to indemnify the Sales Agent against certain civil
liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our common stock as contemplated in this prospectus will be settled
through the facilities of The Depository Trust Company or by such other means as we and the Sales Agent may agree upon. There is no arrangement for funds to be received in escrow, trust or similar arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of our common stock pursuant to the ATM Sales Agreement will terminate on the earlier of (1)&nbsp;the issuance and sale of all of
our common stock subject to the ATM Sales Agreement, or (2)&nbsp;termination of the ATM Sales Agreement by us or the Sales Agent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationships
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sales Agent and its affiliates may provide from time to time in the future certain commercial banking, financial advisory,
investment banking and other services for us in the ordinary course of their business, for which they may receive customary fees and commissions. In addition, from time to time, the Sales Agent and its affiliates may effect transactions for their
own accounts or the account of customers, and hold on behalf of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. Except as disclosed in this prospectus supplement, we have no
present arrangements with the Sales Agent for any further services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on
the Nasdaq Capital Market under the symbol &#8220;INKT.&#8221; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP. The NBD Group, Inc. is counsel to
the Sales Agent in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_10"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of MiNK Therapeutics, Inc. as of December&nbsp;31, 2024 and 2023 and for the years then ended, have been
incorporated by reference herein and in the Registration Statement in reliance on the report of KPMG LLP, an independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in auditing
and accounting. The audit report covering the December&nbsp;31, 2024 consolidated financial statements contains an explanatory paragraph that states that the Company has suffered recurring losses from operations and has a net capital deficiency that
raises substantial doubt about the entity&#8217;s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="txb62147_11"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus supplement and the accompanying prospectus are a part of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed with the SEC. This prospectus does not contain all of the information included in the registration
statement. For further information pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the
references are not necessarily complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information requirements of the Exchange Act and file annual, quarterly and special reports, proxy statements and other
information with the SEC. We file many of our documents electronically with the SEC, and you may access those documents over the Internet. The SEC maintains a web site that contains reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC. The address of the SEC&#8217;s website is http://www.sec.gov. Documents we have filed with the SEC are also available on our website through the investor link at www.minktherapeutics.com.
Information contained on our web site does not constitute a part of this prospectus and is not incorporated by reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our web
site address is <I>minktherapeutics.com</I>. The information on our web site, however, is not, and should not be deemed to be, a part of this prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information into this prospectus supplement and the accompanying prospectus, which means that we can disclose important information to you by referring you to another document
filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement and the accompanying prospectus, and subsequent information that we file with the SEC will automatically update and supersede
that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement
contained in this prospectus supplement or the accompanying prospectus modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference
the following information or documents that we have filed with the SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025041379/inkt-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;18, 2025. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly periods ended
March&nbsp;31, 2025 and June&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025072789/inkt-20250331.htm">May&nbsp;
15, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025108894/inkt-20250630.htm">August&nbsp;14, 2025</A>, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000119312525009595/d926991d8k.htm">January&nbsp;21,
 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1840229/000095017025087888/inkt-20250618.htm">June&nbsp;
18, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001840229/000095017025095460/inkt-20250711.htm">July&nbsp;
14, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001840229/000119312525159017/d99462d8k.htm">July&nbsp;
15, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001840229/000119312525221863/inkt-20250923.htm">September&nbsp;29, 2025</A>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our annual Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000095017025061041/mink-def_14a_2025.htm">Schedule
 14A</A> relating to our annual meeting of stockholders, filed on April&nbsp;30, 2025 (with respect to those portions incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2024). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521297781/d232393d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40908)</FONT> filed with the SEC on October&nbsp;13, 2021, including any amendment or report filed for the purpose of updating such
description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus supplement and accompanying prospectus all reports and
other documents we subsequently file with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, between the date of this prospectus supplement and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
termination of the offering of the securities described in this prospectus supplement. We are not, however, incorporating by reference any documents or portions thereof, whether specifically
listed above or filed in the future, that are not deemed &#8220;filed&#8221; with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant
to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The reports and documents specifically listed above or filed in the future (excluding any information furnished to, rather than filed with, the SEC) are deemed to be part of this
prospectus supplement and accompanying prospectus from the date of the filing of such reports and documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a free copy
of any of the documents incorporated by reference in this prospectus supplement and the accompanying prospectus (other than exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the
following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MiNK Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>149 Fifth Avenue, Suite 500 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10010 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Attention: Investor Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Telephone: (212) <FONT STYLE="white-space:nowrap">994-8250</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Exhibits&nbsp;to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this
prospectus supplement and the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $50,000,000 of Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g62147g34x50.jpg" ALT="LOGO" STYLE="width:2.81482in;height:0.894618in;">
 </P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Sales Agent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>B. RILEY SECURITIES </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>, 2025 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;14. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Set forth below is an estimate (except in the case of the registration fee) of the amount of fees and expenses to be incurred in connection
with the issuance and distribution of the offered securities registered hereby, other than underwriting discounts and commission, if any, incurred in connection with the sale of the offered securities. All such amounts will be borne by MiNK
Therapeutics, Inc. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC Registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,853.23(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trustee fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The $150,000,000 of securities registered pursuant to this registration statement includes $35,204,683 of
securities (the &#8220;Unsold Securities&#8221;) registered pursuant to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> <FONT STYLE="white-space:nowrap">(No.&nbsp;333-268143).</FONT> Pursuant to Rule 415(a)(6) under
the Securities Act of 1933, as amended, the filing fees previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated expenses are not presently known. The foregoing sets forth the general categories of expenses (other
than underwriting discounts and commissions) that we anticipate we will incur in connection with the offering of securities under this registration statement on Form S-3. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;15. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As permitted by Section&nbsp;102(b)(7) of the DGCL, our Amended and Restated Certificate of Incorporation includes a provision to eliminate the
personal liability of our directors for monetary damages for breach of their fiduciary duties as directors, subject to certain exceptions. In addition, our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provides
that we are required to indemnify our officers and directors under certain circumstances, including those circumstances in which indemnification would otherwise be discretionary, and we are required to advance expenses to our officers and directors
as incurred in connection with proceedings against them for which they may be indemnified, in each case except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(a) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the
person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other
enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if the person acted in good faith and in a
manner the person reasonably believed to be in or not opposed to the best interest of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any
action, suit or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent shall not, of itself, create a presumption that the person did not act in good faith and
in a manner which the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that his conduct was unlawful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the DGCL provides that a corporation shall have the power to indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person is or was a director, officer, employee or agent of
the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#8217; fees)
actually and reasonably incurred by him in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the
corporation and except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the
court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with our
directors and certain of our officers. These indemnification agreements provide broader indemnity rights than those provided under the DGCL and our Amended and Restated Certificate of Incorporation. These indemnification agreements are not intended
to deny or otherwise limit third-party or derivative suits against us or our directors or officers, but to the extent a director or officer were entitled to indemnity or contribution under the indemnification agreement, the financial burden of a
third-party suit would be borne by us, and we would not benefit from derivative recoveries against the director or officer. Such recoveries would accrue to our benefit but would be offset by our obligations to the director or officer under the
indemnification agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain directors&#8217; and officers&#8217; liability insurance for the benefit of our directors and
officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;16. Exhibits and Financial Statement Schedules </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a list of exhibits filed as part of this registration statement.<B>&nbsp;</B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;1.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312525159017/d99462dex11.htm">At Market Issuance Sales Agreement, dated as of July&nbsp;
15, 2025, between MiNK Therapeutics, Inc. and B. Riley Securities, Inc. (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)
</FONT> filed on July&nbsp;15, 2025) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521303045/d134002dex31.htm">Amended and Restated Certificate of Incorporation of MiNK Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s
 Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed on October&nbsp;20, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312525009595/d926991dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MiNK Therapeutics, Inc. (incorporated by reference to Exhibit
 3.1 to the Company&#8217;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> <FONT STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;001-40908)</FONT> filed on January&nbsp;21, 2025) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;3.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521303045/d134002dex32.htm">Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> of MiNK Therapeutics, Inc. (incorporated by reference to Exhibit&nbsp;
3.2 to the Company&#8217;s Form <FONT STYLE="white-space:nowrap">8-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed on October&nbsp;20, 2021) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312521296215/d111280dex41.htm">Specimen stock certificate evidencing shares of common stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Form <FONT
STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259503),</FONT> as amended, filed on October&nbsp;12, 2021) </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit&nbsp;No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000156459022011026/inkt-ex42_268.htm">Description of Securities (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-40908)</FONT> filed on March&nbsp;18, 2022) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Share Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Common Stock Warrant Agreement and Warrant Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.5*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Preferred Stock Warrant Agreement and Warrant Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.6*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Debt Securities Warrant Agreement and Warrant Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;4.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1840229/000119312522277009/d290673dex47.htm">Form of Indenture (incorporated by reference to Exhibit 4.7 to the Company&#8217;s Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-268143)</FONT> filed on November&nbsp;3, 2022) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&#8199;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d62147dex51.htm">Opinion of Latham&nbsp;&amp; Watkins LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d62147dex231.htm">Consent of KPMG LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d62147dex51.htm">Consent of Latham&nbsp;&amp; Watkins LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#ii62147_asig">Powers of Attorney (included on the signature page) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>25.1**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Statement of Eligibility of Trustee Under Debt Indenture</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>107</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d62147dexfilingfees.htm">Filing Fee Table </A></TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed, if necessary, subsequent to the effectiveness of this registration statement by an amendment to
this registration statement or incorporated by reference pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> in connection with an offering of securities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To be filed in accordance with the requirements of Section&nbsp;305(b)(2) of the Trust Indenture Act of 1939
and Rule <FONT STYLE="white-space:nowrap">5b-3</FONT> thereunder. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&#8201;17. Undertakings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The undersigned registrant hereby undertakes: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration
statement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with
the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the
effective registration statement; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) To include any material information with respect to the plan of distribution
not previously disclosed in the registration statement or any material change to such information in the registration statement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>provided</I>,<I> however</I>,<I> </I>that the undertakings set forth in paragraphs (a)(1)(i), (a)(I)(ii) and (a)(I)(iii) of
this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b)
that is part of the registration statement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) That, for the purpose of determining any liability under the Securities
Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain
unsold at the termination of the offering; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) That, for the purpose of determining liability under the Securities Act to
any purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in
reliance on Rule 430B relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii) or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and included in
the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in prospectus. As provided in Rule 430B, for
liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which the prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. <I>Provided</I>, <I>however</I>, that no statement made in a registration statement or prospectus that is part of the
registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to
such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(5) That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial
distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities
to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such
purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to
be filed pursuant to Rule 424; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the
undersigned registrant or used or referred to by the undersigned registrant; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) The portion of any other free writing
prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of an undersigned registrant; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(6) That, for purposes of determining any liability under the Securities Act, each filing of registrant&#8217;s annual report
pursuant to Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial bona fide offering thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(7) That, for purposes of determining liability under
the Securities Act: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon 430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was
declared effective; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) each post-effective amendment that contains a form of prospectus shall be deemed a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(8) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(9) If and when applicable, the undersigned registrant hereby undertakes to file an application for the purpose of determining
the eligibility of the trustee to act under subsection (a)&nbsp;of Section&nbsp;310 of the Trust Indenture Act in accordance with the rules and regulations prescribed by the Commission under Section&nbsp;305(b)(2) of the Trust Indenture Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ii62147_asig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of
New&nbsp;York, New York, on the 6th day of November, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MINK THERAPEUTICS, INC</B>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer S. Buell, Ph.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jennifer S. Buell, Ph.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>President, Chief Executive Officer and Director</I></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jennifer S. Buell, Ph.D. and
Christine M. Klaskin, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, with full power of substitution and revocation, for him or her and in his or her name,
place and stead, in any and all capacities, to execute any or all amendments including any post-effective amendments and supplements to this Registration Statement, and any additional Registration Statement filed pursuant to Rule 462(b), and to file
the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and
agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons
in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jennifer S. Buell, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jennifer S. Buell, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">President, Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Christine M. Klaskin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Christine M. Klaskin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Treasurer (Principal Financial Officer and Principal Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Garo H. Armen, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Garo H. Armen, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6,&nbsp;2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Peter Behner</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Peter Behner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Brian Corvese</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brian Corvese</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ John B. Holcomb, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">John B. Holcomb, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Robert Kadlec</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Robert Kadlec</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Barbara Ryan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Barbara Ryan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Ulf Wiinberg</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ulf Wiinberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">November&nbsp;6, 2025</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d62147dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ROWSPAN="5">


<IMG SRC="g62147dsp58.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">200 Clarendon Street</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Boston, Massachusetts 02116</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Tel: +1.617.948.6000 Fax: +1.617.948.6001</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">www.lw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">FIRM / AFFILIATE OFFICES</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Austin</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Milan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Beijing</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Munich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Boston</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Brussels</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Orange County</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chicago</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Paris</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dubai</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Riyadh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">November&nbsp;7, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">D&uuml;sseldorf</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">San Diego</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Frankfurt</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">San Francisco</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hamburg</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Seoul</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Hong Kong</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Silicon Valley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Houston</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Singapore</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">London</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tel Aviv</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Los Angeles</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Tokyo</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Madrid</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Washington, D.C.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MiNK Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">149
Fifth Street, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10010 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re:
<U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3;</FONT> shares of Common Stock, $0.00001 par value per share, having an aggregate offering price of up to $50.0</U><U></U><U>&nbsp;million</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the addressee set forth above: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted
as special counsel to MiNK Therapeutics, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection with its filing on the date hereof with the Securities and Exchange Commission (the
&#8220;<B><I>Commission</I></B>&#8221;) of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (as amended, the &#8220;<B><I>Registration Statement</I></B>&#8221;), including a base prospectus (the &#8220;<B><I>Base
Prospectus</I></B>&#8221;), which provides that it will be supplemented by one or more prospectus supplements (each such prospectus supplement, together with the Base Prospectus, a &#8220;<B><I>Prospectus</I></B>&#8221;), under the Securities Act of
1933, as amended (the &#8220;<B><I>Act</I></B>&#8221;), relating to the registration for issue and sale by the Company of up to $150,000,000 aggregate offering amount of (i)&nbsp;shares of the Company&#8217;s common stock, $0.00001 par value per
share (&#8220;<B><I>Common Stock</I></B>&#8221;), (ii) shares of one or more series of the Company&#8217;s preferred stock, $0.00001 par value per share (&#8220;<B><I>Preferred Stock</I></B>&#8221;), (iii) one or more series of the Company&#8217;s
debt securities (collectively, &#8220;<B><I>Debt Securities</I></B>&#8221;) to be issued under an indenture to be entered into between the Company, as issuer, and a trustee (a form of which is included as Exhibit 4.7 to the Registration Statement)
and one or more board resolutions, supplements thereto or officer&#8217;s certificates thereunder (such indenture, together with the applicable board resolution, supplement or officer&#8217;s certificate pertaining to the applicable series of Debt
Securities, the &#8220;<B><I>Applicable Indenture</I></B>&#8221;), (iv) warrants (&#8220;<B><I>Warrants</I></B>&#8221;), and (v)&nbsp;units (&#8220;<B><I>Units</I></B>&#8221;). The Common Stock, Preferred Stock, Debt Securities, Warrants, and Units
are referred to herein collectively as the &#8220;<B><I>Securities</I></B>.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have acted as special counsel to the Company
in connection with the sale through B. Riley Securities, Inc. as the sales agent (the &#8220;<B><I>Sales Agent</I></B>&#8221;) from time to time by the Company of shares of Common Stock (the &#8220;<B><I>Sales Agreement Shares</I></B>&#8221;) having
an aggregate offering price of up to $50,000,000 pursuant to the Registration Statement, the Base Prospectus and the related prospectus supplement for the sale of the Sales Agreement Shares included in the Registration Statement (the Base Prospectus
and such prospectus supplement, collectively, the &#8220;<B><I>Sales Agreement Prospectus</I></B>&#8221;), and that certain At Market Issuance Sales Agreement dated as of July 15, 2025 between the Sales Agent and the Company (the &#8220;<B><I>Sales
Agreement</I></B>&#8221;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>November 7, 2025</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page </B><B>
2</B>
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g62147dsp59.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is being furnished in connection with the requirements of Item 601(b)(5) of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related applicable Prospectus or the Sales Agreement Prospectus,
other than as expressly stated herein with respect to the issue of the Securities, including the issuance of the Sales Agreement Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter.
With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law
of the State of Delaware, and with respect to the opinions set forth in paragraphs 3 through 5 below, the internal laws of the State of New York, and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws
of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. When an issuance of Common Stock has been duly authorized by all necessary corporate action of the Company, upon issuance, delivery and
payment therefor in an amount not less than the par value thereof in the manner contemplated by the applicable Prospectus and by such corporate action, and in total amounts and numbers of shares that do not exceed the respective total amounts and
numbers of shares (a)&nbsp;available under the certificate of incorporation, and (b)&nbsp;authorized by the board of directors in connection with the offering contemplated by the applicable Prospectus, such shares of Common Stock will be validly
issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of
Delaware. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. When a series of Preferred Stock has been duly established in accordance with the terms of the Company&#8217;s Certificate of
Incorporation and authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in the manner contemplated by the applicable Prospectus and by such
corporate action, and in total amounts and numbers of shares that do not exceed the respective total amounts and numbers of shares (a)&nbsp;available under the certificate of incorporation, and (b)&nbsp;authorized by the board of directors in
connection with the offering contemplated by the applicable Prospectus, such shares of such series of Preferred Stock will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will
comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>November 7, 2025</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page </B><B>
3</B>
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g62147dsp59.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. When the Applicable Indenture has been duly authorized, executed and delivered by all
necessary corporate action of the Company, and when the specific terms of a particular series of Debt Securities have been duly established in accordance with the terms of the Applicable Indenture and authorized by all necessary corporate action of
the Company, and such Debt Securities have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the Applicable Indenture and in the manner contemplated by the applicable Prospectus and by
such corporate action, such Debt Securities will be the legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. When the applicable warrant agreement has been duly authorized, executed and delivered by all necessary corporate action of the Company, and
when the specific terms of a particular issuance of Warrants have been duly established in accordance with the terms of the applicable warrant agreement and authorized by all necessary corporate action of the Company, and such Warrants have been
duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the applicable warrant agreement and in the manner contemplated by the applicable Prospectus and by such corporate action (assuming the
securities issuable upon exercise of such Warrants have been duly authorized and reserved for issuance by all necessary corporate action), such Warrants will be the legally valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. When the applicable unit agreement has been duly authorized, executed and delivered by all
necessary corporate action of the Company, and when the specific terms of a particular issuance of Units have been duly authorized in accordance with the terms of the applicable unit agreement and authorized by all necessary corporate action of the
Company, and such Units have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the applicable unit agreement and in the manner contemplated by the applicable Prospectus and by such
corporate action (assuming the securities issuable upon exercise of such Units have been duly authorized and reserved for issuance by all necessary corporate action), such Units will be the legally valid and binding obligations of the Company,
enforceable against the Company in accordance with their terms. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. Upon the completion of all Corporate Proceedings (as defined below)
relating to the Sales Agreement Shares, when the Sales Agreement Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against
payment therefor (not less than par value) in accordance with the Corporate Proceedings and the terms of the Sales Agreement, the issuance and sale of the Sales Agreement Shares will have been duly authorized by all necessary corporate action of the
Company, and the Sales Agreement Shares will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that (i)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated
shares provided in the General Corporation Law of the State of Delaware (the &#8220;<B><I>DGCL</I></B>&#8221;), (ii) upon the issuance of any of the Sales Agreement Shares, the total number of shares of Common Stock issued and outstanding will not
exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Company&#8217;s certificate of incorporation and (iii)&nbsp;certain terms of the Sales Agreement Shares to be issued by the Company from time to
time will be authorized and approved by the board of directors of the Company or one or more committees thereof established by the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>November 7, 2025</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page </B><B>
4</B>
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g62147dsp59.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
board of directors of the Company with the authority to issue and sell Sales Agreement Shares pursuant to the Sales Agreement in accordance with the DGCL, the Company&#8217;s certificate of
incorporation, the <FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company and certain resolutions of the board of directors of the Company and one or more committees thereof (with such approvals referred to herein as the
&#8220;<B><I>Corporate Proceedings</I></B>&#8221;) prior to issuance thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinions are subject to: (i)&nbsp;the effect of
bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors; (ii)&nbsp;(a) the effect of general principles of equity, whether considered in
a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), (b) concepts of materiality, reasonableness, good faith and fair dealing, and (c)&nbsp;the discretion of the court before which a
proceeding is brought; and (iii)&nbsp;the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or
contribution is contrary to public policy. We express no opinion as to (a)&nbsp;any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions
are deemed to constitute a penalty, (b)&nbsp;consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief, (c)&nbsp;waivers of rights or defenses, (d)&nbsp;any provision requiring the payment of
attorneys&#8217; fees, where such payment is contrary to law or public policy, (e)&nbsp;any provision permitting, upon acceleration of any Debt Securities, collection of that portion of the stated principal amount thereof which might be determined
to constitute unearned interest thereon, (f)&nbsp;the creation, validity, attachment, perfection, or priority of any lien or security interest, (g)&nbsp;advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing,
evidentiary requirements, statutes of limitation, trial by jury or at law, or other procedural rights, (h)&nbsp;waivers of broadly or vaguely stated rights, (i)&nbsp;provisions for exclusivity, election or cumulation of rights or remedies,
(j)&nbsp;provisions authorizing or validating conclusive or discretionary determinations, (k)&nbsp;grants of setoff rights, (l)&nbsp;proxies, powers and trusts, (m)&nbsp;provisions prohibiting, restricting, or requiring consent to assignment or
transfer of any right or property, (n)&nbsp;any provision to the extent it requires that a claim with respect to a security denominated in other than U.S. dollars (or a judgment in respect of such a claim) be converted into U.S. dollars at a rate of
exchange at a particular date, to the extent applicable law otherwise provides, and (o)&nbsp;the severability, if invalid, of provisions to the foregoing effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With your consent, we have assumed (a)&nbsp;that each of the Debt Securities, Warrants, Units and the Applicable Indenture, warrant
agreements, and unit agreements governing such Securities (collectively, the &#8220;<B><I>Documents</I></B>&#8221;) will be governed by the internal laws of the State of New York, (b)&nbsp;that each of the Documents has been or will be duly
authorized, executed and delivered by the parties thereto, (c)&nbsp;that each of the Documents constitutes or will constitute legally valid and binding obligations of the parties thereto other than the Company, enforceable against each of them in
accordance with their respective terms, and (d)&nbsp;that the status of each of the Documents as legally valid and binding obligations of the parties will not be affected by any (i)&nbsp;breaches of, or defaults under, agreements or instruments,
(ii)&nbsp;violations of statutes, rules, regulations or court or governmental orders, or (iii)&nbsp;failures to obtain required consents, approvals or authorizations from, or to make required registrations, declarations or filings with, governmental
authorities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>November 7, 2025</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Page </B><B>
5</B>
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g62147dsp59.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is for your benefit in connection with the Registration Statement and may be
relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm contained in each of the
Prospectus and the Sales Agreement Prospectus under the heading &#8220;Legal Matters.&#8221; We further consent to the incorporation by reference of this letter and consent into any registration statement or post-effective amendment to the
Registration Statement filed pursuant to Rule 462(b) under the Act with respect to the Securities. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or
the rules and regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d62147dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our report dated March&nbsp;18, 2025, with respect to the consolidated financial statements of MiNK Therapeutics, Inc., incorporated
herein by reference, and to the reference to our firm under the heading &#8220;Experts&#8221; in the prospectus and prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston,
Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;7, 2025 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>d62147dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
<title>EX-FILING FEES</title>
</head>
  <body>
  <div style="display: none"> <ix:header> <ix:hidden> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-500">S-3</ix:nonNumeric> <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-501">S-3</ix:nonNumeric> <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-502">EX-FILING FEES</ix:nonNumeric> <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-503">0001840229</ix:nonNumeric> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-504">MiNK Therapeutics, Inc.</ix:nonNumeric> <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric> <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric> <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-508">0.0001381</ix:nonFraction> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-509">0.0001381</ix:nonFraction> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_3" id="ixv-510">0.0001381</ix:nonFraction> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_4" id="ixv-511">0.0001381</ix:nonFraction> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_5" id="ixv-512">0.0001381</ix:nonFraction> </ix:hidden> <ix:references> <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/> </ix:references> <ix:resources> <xbrli:context id="rc"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>1</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_2"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>2</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_3"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>3</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_4"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>4</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_5"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>5</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_6"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>6</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_7"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>7</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_8"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>8</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_9"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>9</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>10</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_11"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>11</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="offrl_12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840229</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ffd:OfferingAxis"> <dei:lineNo>12</dei:lineNo> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-07</xbrli:startDate> <xbrli:endDate>2025-11-07</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:unit id="USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit> <xbrli:unit id="pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit> <xbrli:unit id="Shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit> </ix:resources> </ix:header> </div> <div>
<table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
<tr>
<td colspan="4" style="padding-bottom: .5em"> <p> <b>Calculation of Filing Fee Tables</b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-636">S-3</ix:nonNumeric> </b> </p> </td> </tr>
<tr>
<td style="padding-bottom: .25em"> <p> <b> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-637">MiNK Therapeutics, Inc.</ix:nonNumeric> </b> </p> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 1: Newly Registered and Carry Forward Securities</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
<tr style="background-color:#9ADAF6">
<th style="width: 12%;">
 </th>
<th style="width: 2%;">
 </th>
<th style="width: 12%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 14%;"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title </b> </p> </th>
<th style="width: 2%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Calculation or Carry Forward Rule</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount Registered</b> </p> </th>
<th style="width: 15%;"> <p style="margin: 0pt; text-align: center;"> <b>Proposed Maximum Offering Price Per Unit</b> </p> </th>
<th style="width: 10%;"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price</b> </p> </th>
<th style="width: 5%;"> <p style="margin: 0pt; text-align: center;"> <b>Fee Rate</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Registration Fee</b> </p> </th>
<th style="width: 1%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Form Type</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward File Number</b> </p> </th>
<th style="width: 6%;"> <p style="margin: 0pt; text-align: center;"> <b>Carry Forward Initial Effective Date</b> </p> </th>
<th style="width: 7%;"> <p style="margin: 0pt; text-align: center;"> <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b> </p> </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Newly Registered Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-638">Equity</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-639">Common Stock, par value $0.00001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-640">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-641">Equity</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-642">Preferred Stock, par value $0.00001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-643">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_3" id="ixv-644">Other</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_3" id="ixv-645">Warrants</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_3" format="ixt:booleantrue" id="ixv-646">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_4" id="ixv-647">Debt</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_4" id="ixv-648">Debt Securities</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_4" format="ixt:booleantrue" id="ixv-649">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_5" id="ixv-650">Other</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_5" id="ixv-651">Units</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_5" format="ixt:booleantrue" id="ixv-652">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_6" format="ixt:booleanfalse" id="ixv-653">Fees to be Paid</ix:nonNumeric> </td>
<td style="text-align: center;"> 1 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_6" id="ixv-654">Unallocated (Universal) Shelf</ix:nonNumeric> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_6" format="ixt:booleantrue" id="ixv-655">457(o)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_6" id="ixv-656">114,795,317.00</ix:nonFraction> </td>
<td style="text-align: right;"> <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_6" id="ixv-657">0.0001381</ix:nonFraction> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_6" id="ixv-658">15,853.23</ix:nonFraction> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fees Previously Paid </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: center;"> </td>
<td style="text-align: right;"> </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Carry Forward Securities</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_7" id="ixv-659">Equity</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_7" id="ixv-660">Common Stock, par value $0.00001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule415a6Flg" contextRef="offrl_7" format="ixt:booleantrue" id="ixv-661">415(a)(6)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdFormTp" contextRef="offrl_7" id="ixv-662">S-3</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFileNb" contextRef="offrl_7" id="ixv-663">333-268143</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFctvDt" format="ixt:datemonthdayyear" contextRef="offrl_7" id="ixv-664">11/08/2022</ix:nonNumeric> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_8" id="ixv-665">Equity</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_8" id="ixv-666">Preferred Stock, par value $0.00001 per share</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule415a6Flg" contextRef="offrl_8" format="ixt:booleantrue" id="ixv-667">415(a)(6)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdFormTp" contextRef="offrl_8" id="ixv-668">S-3</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFileNb" contextRef="offrl_8" id="ixv-669">333-268143</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFctvDt" format="ixt:datemonthdayyear" contextRef="offrl_8" id="ixv-670">11/08/2022</ix:nonNumeric> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_9" id="ixv-671">Other</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_9" id="ixv-672">Warrants</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule415a6Flg" contextRef="offrl_9" format="ixt:booleantrue" id="ixv-673">415(a)(6)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdFormTp" contextRef="offrl_9" id="ixv-674">S-3</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFileNb" contextRef="offrl_9" id="ixv-675">333-268143</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFctvDt" format="ixt:datemonthdayyear" contextRef="offrl_9" id="ixv-676">11/08/2022</ix:nonNumeric> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_10" id="ixv-677">Debt</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_10" id="ixv-678">Debt Securities</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule415a6Flg" contextRef="offrl_10" format="ixt:booleantrue" id="ixv-679">415(a)(6)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdFormTp" contextRef="offrl_10" id="ixv-680">S-3</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFileNb" contextRef="offrl_10" id="ixv-681">333-268143</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFctvDt" format="ixt:datemonthdayyear" contextRef="offrl_10" id="ixv-682">11/08/2022</ix:nonNumeric> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> </td>
<td style="text-align: left;"> <span style="text-indent: 0px; display:inline-block; padding-left: 20px;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_11" id="ixv-683">Other</ix:nonNumeric> </span> </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_11" id="ixv-684">Units</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule415a6Flg" contextRef="offrl_11" format="ixt:booleantrue" id="ixv-685">415(a)(6)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdFormTp" contextRef="offrl_11" id="ixv-686">S-3</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFileNb" contextRef="offrl_11" id="ixv-687">333-268143</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFctvDt" format="ixt:datemonthdayyear" contextRef="offrl_11" id="ixv-688">11/08/2022</ix:nonNumeric> </td>
<td style="text-align: right;"> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Carry Forward Securities </td>
<td style="text-align: center;"> 2 </td>
<td style="text-align: left;"> <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_12" id="ixv-689">Unallocated (Universal) Shelf</ix:nonNumeric> </td>
<td style="text-align: left;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:Rule415a6Flg" contextRef="offrl_12" format="ixt:booleantrue" id="ixv-690">415(a)(6)</ix:nonNumeric> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_12" id="ixv-691">35,204,683.00</ix:nonFraction> </td>
<td style="text-align: right;"> </td>
<td style="text-align: right;"> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdFormTp" contextRef="offrl_12" id="ixv-692">S-3</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFileNb" contextRef="offrl_12" id="ixv-693">333-268143</ix:nonNumeric> </td>
<td style="text-align: center;"> <ix:nonNumeric name="ffd:CfwdPrrFctvDt" format="ixt:datemonthdayyear" contextRef="offrl_12" id="ixv-694">11/08/2022</ix:nonNumeric> </td>
<td style="text-align: right;"> <span>$</span> <ix:nonFraction name="ffd:CfwdPrevslyPdFee" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="offrl_12" id="ixv-695">3,879.56</ix:nonFraction> </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p> </td>
<td>
 </td>
<td style="vertical-align: top; width: 16%;"> <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-696">150,000,000.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td style="vertical-align: top; border-bottom: 1px black; width: 16%;"> <p id="TotalFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-697">15,853.23</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fees Previously Paid: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-698">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Total Fee Offsets: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-699">0.00</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr>
<tr>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td colspan="3" style="vertical-align: top"> <p style="margin: 0pt; text-align: right"> Net Fee Due: </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td style="vertical-align: top"> <p id="NetFeeAmt" style="margin: 0pt; text-align: right"> <span>$</span> <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="ixv-700">15,853.23</ix:nonFraction> </p> </td>
<td>
 </td>
<td>
 </td>
<td>
 </td>
<td>
 </td> </tr> </table> </div> <div>
<table style="width: 100%; text-indent: 0px;"> <tbody>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td> <p style="margin:0pt;text-align:left; margin-bottom: 5px;"> <b>Offering Note</b> </p> </td>
<td/> </tr> </tbody> </table> </div> <div style="padding-bottom: 20px;">
<table style="width: 100%; text-indent: 0px;">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_6" id="ixv-701">1(a) Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $150,000,000. 1(b) An indeterminate amount of common stock, preferred stock, warrants, debt securities and/or units is being registered as may from time to time be offered hereunder at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. 1(c) The $150,000,000 of securities registered pursuant to this registration statement includes $50,000,000 of common stock that may be issued and sold under a certain sales agreement with B. Riley Securities, Inc. Upon termination of the sales agreement, any portion of the $50,000,000 included in the sales agreement prospectus supplement that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. 1(d) Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $35,204,683 of unsold securities (the "Unsold Securities") previously registered pursuant to the Registration Statement on Form S-3 (File No. 333-268143), which was declared effective on November 8, 2022 (the "Prior Registration Statement"). The registrant sold an aggregate of $14,795,317 of securities under the Prior Registration Statement, leaving the balance of $35,204,683 of Unsold Securities, in respect of which the registrant paid a filing fee of $3,879.56 (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement) in connection with the filing of the Prior Registration Statement. Pursuant to Rule 415(a)(6), the filing fee of $3,879.56 associated with the offering of the Unsold Securities is hereby carried forward to be applied to $35,204,683 of Unsold Securities registered hereunder, and as a result, no additional filing fee is due with respect to the Unsold Securities included in this registration statement. Pursuant to Rule 415(a)(6), the offering of securities under the Prior Registration Statement will be deemed terminated as of the time of effectiveness of this registration statement.</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr>
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
<td style="width:10pt;"> <p style="margin:0pt;text-align:left;"> <sup style="vertical-align:top;line-height:120%;font-size:10px">2</sup> </p> </td>
<td colspan="7" style="white-space: pre-line;"> <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_12" id="ixv-702">See Offering Note 1(d)</ix:nonNumeric> </td> </tr>
<tr>
<td colspan="7"> <hr style="width:100%;text-align:left;margin-left:0"/> </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 2: Fee Offset Claims and Sources</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 10%; text-align: left;">
 </th>
<th style="width: 8%; text-align: left;">
 </th>
<th style="width: 16%;"> Registrant or Filer Name </th>
<th style="width: 6%;"> Form or Filing Type </th>
<th style="width: 7%;"> File Number </th>
<th style="width: 6%;"> Initial Filing Date </th>
<th style="width: 6%;"> Filing Date </th>
<th style="width: 6%;"> Fee Offset Claimed </th>
<th style="width: 6%;"> Security Type Associated with Fee Offset Claimed </th>
<th style="width: 8%;"> Security Title Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Unsold Securities Associated with Fee Offset Claimed </th>
<th style="width: 9%;"> Unsold Aggregate Offering Amount Associated with Fee Offset Claimed </th>
<th style="width: 6%;"> Fee Paid with Fee Offset Source </th> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rules 457(b) and 0-11(a)(2)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr>
<td colspan="14" style="text-align: center"> <b>Rule 457(p)</b> </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Claims </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr>
<tr style="background-color:#E7E7E2">
<td style="text-align: left;"> Fee Offset Sources </td>
<td> N/A </td>
<td style="text-align: left;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: left;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td> </tr> </table> </div> <div style="padding-bottom: 20px;">
<table style="float: center; width: 100%; text-align: left; ">
<tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
<th style="vertical-align: bottom; text-align: left; word-wrap: break-word"> <b>Table 3: Combined Prospectuses</b> </th>
<th style="vertical-align: bottom; word-wrap: break-word; text-align: right;"> <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span> </th> </tr> </table>
<table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
<tr style="background-color:#9ADAF6">
<th style="width: 4%">
 </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Security Type</b> </p> </th>
<th style="width: 25%"> <p style="margin: 0pt; text-align: center;"> <b>Security Class Title</b> </p> </th>
<th style="width: 14%"> <p style="margin: 0pt; text-align: center;"> <b>Amount of Securities Previously Registered</b> </p> </th>
<th style="width: 18%"> <p style="margin: 0pt; text-align: center;"> <b>Maximum Aggregate Offering Price of Securities Previously Registered</b> </p> </th>
<th style="width: 6%"> <p style="margin: 0pt; text-align: center;"> <b>Form Type</b> </p> </th>
<th style="width: 10%"> <p style="margin: 0pt; text-align: center;"> <b>File Number</b> </p> </th>
<th style="width: 8%"> <p style="margin: 0pt; text-align: center;"> <b>Initial Effective Date</b> </p> </th> </tr>
<tr style="background-color:#E7E7E2;">
<td style="text-align: center;"> N/A </td>
<td> N/A </td>
<td> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: right;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td>
<td style="text-align: center;"> N/A </td> </tr> </table> </div> </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g62147dsp58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62147dsp58.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  M /P# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z "@ H
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M3- '1T % !0 4 ?)'[ '_(;_ &E_^RNZ[_Z&E 'U9J^JVFA:3>ZE?S+;6-G
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M\<_#^P\/^+O%FH^)EM]7LKF>XC-Q*2JL0F 0@0$#(R#S0!Z_\4OA;\6?B?\
MLFZMX#O/$7AZ+XCZU9M8:AK,"30V'E/*?-\M0I<$P?)TZDF@#*TG_@GI\";+
MP)9Z!=?#O0KJ]BTU+&75S:C[3)((@C3[^N\G+9]30!T7[&OP7\6_L]_ S3?
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M;3BP(DC8%=NW'EJ,,>(QZT :/AC]GG6M#_;-\7?&*74K"30M9\-0Z+%8)O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
LH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g62147dsp59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62147dsp59.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  6 *\# 1$  A$! Q$!_\0
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M;R+;21&03%KF:),#Y5*ABV7'& 2 #!^!?[0L_P ;O 3>-%\":WX9\-36(O\
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% 4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g62147g04x33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62147g04x33.jpg
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M*"@H*"@H*"@H*/_  !$( 20#CP,!(@ "$0$#$0'_Q  <  $  P$! 0$!
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MH&KMY 0!ESYJG5O2KIH*NFDIZN&.:"1NJ^.1H<UPY"#O5>UNA?!M55&9M#/
M"<S'#.X,]1SR[$0S+A+#U;B>^TUKML9=+*[RGY>3&SC>[F'_ &6V+91Q6ZVT
ME%3C*&FB9"P?V6@ ?4%X,,X9L^&:5U/8Z"*E8[W[FYE[_E..T]I781(B(@*+
M:5/1SB+J<GL4I46TJ>CG$74Y/8@Q>B(B!$1!+=&&+I<'8I@KLW.HI/T55&/C
M1D[\N4;QT9<:V12SQ55-%44TC9(96!['M.8<TC,$+!2T-X..-O&*9V%[C+^F
MA!DHG./OF;W1]F\<V?(A"\T1$2(B("(B B(@+"5Y^%Z[Y]_>*W:L)7GX7KOG
MW]XHAXT1$&S]%/HYP[U-BE2BNBGT<X=ZFQ2I$B(B"-Z2_1[B/J$W<*Q4MJZ2
M_1[B/J$W<*Q4B!>_#_P];>LQ=X+P+WX?^'K;UF+O!!NI$1$B(B B(@(BK#3#
MI-APG3/MMI>R:^2MZ6TS3\9W]KD':=F\&F'2;#A.F?;;2]DU\E;TMIFGXSO[
M7(.T[-^6JJHFJZF6HJI7S3RN+WR/.;G..\DI55$U74RU%5*^:>5Q>^1YS<XG
M>25^2($12C1]@NXXTO I*$<'31Y&HJ7#-L3?O)XAQ]&90?. <&W'&=X;1V]N
MI P@U%2X>1"WE/*3Q#C]96NL(X:MV%;-%;;3"&1-VO>??RNXW./&?_\ %_<)
MX<MV%K-#;;3#J0LVN>??2.XW./&2NPB1$1 1%"M*N)C8,/F&F?JU]9G'$1O8
MWXSOKR'.>98VM%8WE=I\%M1EKBIUE -+F,#=:YUHM\G\PIW?I7-.R60?</;M
MY%6Z(N5>\WG>7TK2Z:FEQ1BQ](_S[Q$18M@1$0$1$!$1 1$0$1$!$1 5T:',
M8&JB%AN,F<T;<Z5[C[YHWLZ1Q<W0J77[4=3-1U4-332&.>)P>QXW@@YA9X\D
MX[;PTM?HJ:S#..W7PGV2ULBXV$+Y%B&P4UPBR#WC5E8/B/'OA]_00NRNK$Q,
M;P^;Y,=L=II:-I@1$4L!$1 1$0$1$!$1 1$0$1$!4_X3WF3;OI!OV<BN!4_X
M3WF3;OI!OV<B#,R(B($7[Q4DTM)45,;=:* M$A'Q=;, ^L9=H7X("UWH/Q![
MO:/J'A'ZU30_S.7/?Y.6J?[I;]:R(K@\&K$'B&*ZFSS/RAN,6; ?ZUF9'K;K
M>H(0TRB(B1$1 1$0$1$!$7YU,\=-3RSSO#(8F%[W'<UH&9/U(,^^$[B'AJ^W
M6"!_D0-\:G _7=F& ] S/[RHQ=C%]ZDQ%B:Y76;/.JF+V@_%9N:WL: .Q<=$
M"+ZBC=+(R.-I<]Y#6M S))W!?=5 ^EJIJ>8 21/,;@#N(.1]B#\D1$&W,!>8
M^'OH^G^S:NZN%@+S'P]]'T_V;5W42(B("(B B(@(B("BVE3T<XBZG)[%*5%M
M*GHYQ%U.3V(,7HB(@1>RSTS*R[4--*7".:=D;M7?D7 ')>W%^'ZK#&(:RTUP
M_20/\E^60D8?>N',0@XR]5JN%3:KE35]#*8JJGD$D;QQ$+RH@VU@3$U-BW#5
M)=:7)KGC5FCSSX.0>^;_ *<Q"[ZR?H-QK^2V)125LNK:K@1'+F=D;]S7_<>8
M\RU@B1$1 1$0$1$!82O/PO7?/O[Q6[5A*\_"]=\^_O%$/&B(@V?HI]'.'>IL
M4J45T4^CG#O4V*5(D1$01O27Z/<1]0F[A6*EM727Z/<1]0F[A6*D0+WX?^'K
M;UF+O!>!>_#_ ,/6WK,7>"#=2(B)$1$!$56Z8=)\.%:=]KM#V37R1NT[VTP/
MQG<KN0=IXLP_NF'2?#A2G?;+0YDU\D;MXVTP/QG<KN0=IV;\N5=1-5U,M152
MOFGE<7OD><W.<=Y)2JJ)JJHEJ*F5\L\KB]\CSFYQ.\DK\D0(BE>CO!%QQK=Q
M348,5'$0:FJ</)C;][CQ#[D'SH]P5<,:7@4M$#%2QY&HJ7#-L3?O<>(?=FM<
MX5P[;L,6>&VVF$10,VN<=KI'<;G'C)_\V+ZPOA^WX9L\-MM,(BIXQM)VN>[C
M<X\9*ZJ)$1$!$1 6:M(M]-^Q35SL=K4T)X&#DU6D[>TYGM5YZ0KJ;/A"XU+'
M:LSF<%&1OUG>2".C,GL695IZJ_2KUGT:TL?;U$^4?K^@B(M)ZP1$0$1$!$1
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ML&K'5QY,JH =L;_PG>#]X*$)4B(B1$1 1$0$1$!$1!0>FZ#@L9B3+9-31O\
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MND;E1WA/8ASDMF'X'[&CQN< \>UK!WCVA$J&>YSWN<\ESG',D[R5_$1$+)T
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M%:E6CC&-7@O$$==!K24LF3*J#/9(S\0W@_ZE!L]%X[/<Z2\6RFN%NF;-25#
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MU6OH%N,HKKE;BXF%T8J&M/Q7 AIRZ01ZEL8<]IMRV<'BW!<&+!.;!&TQX?\
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MLF]C^(\H.\'G"]Z(*&OW@^L?.Y]AO)CB)V0U<>MJ_OM_T7&_D_7S]KVWU/\
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G$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g62147g34x50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g62147g34x50.jpg
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M*"@H*"@H*"@H*"@H_\  $0@!#0-- P$B  (1 0,1 ?_$ !P  0 " P$! 0
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M54G0KC=V$L2MAK)2+17$1U )V1N^3)U<?,3R!6V!! (((.T$(D1$0$1$!$1
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M8[S+F3X-+.\^ICC[#U<B[<&??S;/)=L=BQ6)SZ>/;'[Q]$NHB+L>4$1$!$1
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M'65Q_P )&/4T!;M:' 7B99?HL?L6^5O3T8?+M3^=?VS\Q$19- B(@(B("(B
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MY$1%S/1+/8"\3++]%C]BWRT. O$RR_18_8M\K>GHP^7:K\Z_MGYB(BR:!$1
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M<-5H?T2QV00WG$L39;IL?#3':VGYSRO^H=.[2Z?]'6J9L462'P3X5?"P;O\
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M'#EIFOM]H+72_E:J9L0.7P03M/0!F>I!8S@W8<]S<)37>=F51<WYL)&T1,)
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MSFU[#D0MT:N>^%7E^S..8GR=YW]?^0MHH8T^?G.T_,O^T%(^ [Z[$.&:6NE
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M6',T](7$R<Q<0,AT9GH5@408Z>&*FIXH*>-L<,30QC&C(-:!D !R+(B("(B
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M7@B(@(B("(OW#%)/*R*%CI)'D-:UHS+B=P 0Z-AANSSWV]4MOI@=:5V3G9?
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M=W_M&KK]U?K?!SRRV?YBM\LL59K2(EI[1STU&IOEQ])V^0HAT_#-]A'+W?\
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MWXZ[>M=]F>3^ZZB,OH^;T]LIW6KQ->J>P66IKZIP C:=1I.U[^)HZ5P;K!I
MM [A:KW%5TPV,,NJ7 ?M@Y>M>:'1]B"_UT=1C"[!T+#^2C=K.YP!D&MZ1FLI
MR6F-HKS:L>AT];<>7-6:>K?>?=MR9M!UNF='=+W5 ZU4_N;''Y61)<?61ZBI
M36"@I(*"CAI:.)L5/$T,8QNX!9UGCIP5V<FMU/WK/;+MM$]/9W"XS2Q8I+UA
M60TS"^II'=W8T;W  AP'4<^I=FBFU8M$Q+5I\]M/EKEKUB7$:*,2PWG#T-'+
M(!7T3!$]A.US!L:X=60//TKMU'>)]''=[D;IAFL-MKR[6+02UA=R@C:WZPO
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I("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Nov. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001840229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">MiNK Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Nov. 07, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Preferred Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Debt Securities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Units<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=6', window );">Offering: 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Unallocated (Universal) Shelf<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 114,795,317.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 15,853.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">1(a) Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $150,000,000. 1(b) An indeterminate amount of common stock, preferred stock, warrants, debt securities and/or units is being registered as may from time to time be offered hereunder at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. 1(c) The $150,000,000 of securities registered pursuant to this registration statement includes $50,000,000 of common stock that may be issued and sold under a certain sales agreement with B. Riley Securities, Inc. Upon termination of the sales agreement, any portion of the $50,000,000 included in the sales agreement prospectus supplement that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. 1(d) Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $35,204,683 of unsold securities (the "Unsold Securities") previously registered pursuant to the Registration Statement on Form S-3 (File No. 333-268143), which was declared effective on November 8, 2022 (the "Prior Registration Statement"). The registrant sold an aggregate of $14,795,317 of securities under the Prior Registration Statement, leaving the balance of $35,204,683 of Unsold Securities, in respect of which the registrant paid a filing fee of $3,879.56 (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement) in connection with the filing of the Prior Registration Statement. Pursuant to Rule 415(a)(6), the filing fee of $3,879.56 associated with the offering of the Unsold Securities is hereby carried forward to be applied to $35,204,683 of Unsold Securities registered hereunder, and as a result, no additional filing fee is due with respect to the Unsold Securities included in this registration statement. Pursuant to Rule 415(a)(6), the offering of securities under the Prior Registration Statement will be deemed terminated as of the time of effectiveness of this registration statement.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=7', window );">Offering: 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule415a6Flg', window );">Rule 415(a)(6)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdFormTp', window );">Carry Forward Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFileNb', window );">Carry Forward File Number</a></td>
<td class="text">333-268143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFctvDt', window );">Carry Forward Initial Effective Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=8', window );">Offering: 8</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule415a6Flg', window );">Rule 415(a)(6)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Preferred Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdFormTp', window );">Carry Forward Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFileNb', window );">Carry Forward File Number</a></td>
<td class="text">333-268143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFctvDt', window );">Carry Forward Initial Effective Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=9', window );">Offering: 9</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule415a6Flg', window );">Rule 415(a)(6)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdFormTp', window );">Carry Forward Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFileNb', window );">Carry Forward File Number</a></td>
<td class="text">333-268143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFctvDt', window );">Carry Forward Initial Effective Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=10', window );">Offering: 10</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule415a6Flg', window );">Rule 415(a)(6)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Debt<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Debt Securities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdFormTp', window );">Carry Forward Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFileNb', window );">Carry Forward File Number</a></td>
<td class="text">333-268143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFctvDt', window );">Carry Forward Initial Effective Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=11', window );">Offering: 11</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule415a6Flg', window );">Rule 415(a)(6)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Units<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdFormTp', window );">Carry Forward Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFileNb', window );">Carry Forward File Number</a></td>
<td class="text">333-268143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFctvDt', window );">Carry Forward Initial Effective Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=12', window );">Offering: 12</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule415a6Flg', window );">Rule 415(a)(6)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Unallocated (Universal) Shelf<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 35,204,683.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdFormTp', window );">Carry Forward Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFileNb', window );">Carry Forward File Number</a></td>
<td class="text">333-268143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrrFctvDt', window );">Carry Forward Initial Effective Date</a></td>
<td class="text">Nov.  08,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CfwdPrevslyPdFee', window );">Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</a></td>
<td class="nump">$ 3,879.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">See Offering Note 1(d)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CfwdFormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., "Form S-3" in the human-readable and "S-3ASR" in the XBRL).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 415<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CfwdFormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:formTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CfwdPrevslyPdFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 415<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CfwdPrevslyPdFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CfwdPrrFctvDt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 415<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CfwdPrrFctvDt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CfwdPrrFileNb">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 415<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CfwdPrrFileNb</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule415a6Flg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is claiming a 415(a)(6) carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 415<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule415a6Flg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br> -Subsection o<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=8">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=8</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=9">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=9</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=10">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=10</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=11">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=11</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=12">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=12</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Nov. 07, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 150,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">15,853.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 15,853.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>13</ContextCount>
  <ElementCount>26</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="d62147dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d62147dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d62147dexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="d62147dexfilingfees.htm">d62147dexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="77">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d62147dexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "d62147dexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 26,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/ffd/2025": 11,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 13,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 77,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d62147dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d62147dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d62147dexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d62147dexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-25-272532-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-272532-xbrl.zip
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9:'1M4$L%!@     !  $ 10   '\1      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>d62147dexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>8</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>9</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>10</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>11</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="offrl_12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840229</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>12</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-500">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-501">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-502">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-503">0001840229</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-504">MiNK Therapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="INF"
      id="ixv-508"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_2"
      decimals="INF"
      id="ixv-509"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_3"
      decimals="INF"
      id="ixv-510"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_4"
      decimals="INF"
      id="ixv-511"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_5"
      decimals="INF"
      id="ixv-512"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FormTp contextRef="rc" id="ixv-636">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-637">MiNK Therapeutics, Inc.</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-638">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-639">Common Stock, par value $0.00001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_1" id="ixv-640">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-641">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-642">Preferred Stock, par value $0.00001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_2" id="ixv-643">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_3" id="ixv-644">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_3" id="ixv-645">Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_3" id="ixv-646">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_4" id="ixv-647">Debt</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_4" id="ixv-648">Debt Securities</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_4" id="ixv-649">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_5" id="ixv-650">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_5" id="ixv-651">Units</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_5" id="ixv-652">true</ffd:Rule457oFlg>
    <ffd:PrevslyPdFlg contextRef="offrl_6" id="ixv-653">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_6" id="ixv-654">Unallocated (Universal) Shelf</ffd:OfferingSctyTp>
    <ffd:Rule457oFlg contextRef="offrl_6" id="ixv-655">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_6"
      decimals="INF"
      id="ixv-656"
      unitRef="USD">114795317.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_6"
      decimals="INF"
      id="ixv-657"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_6"
      decimals="INF"
      id="ixv-658"
      unitRef="USD">15853.23</ffd:FeeAmt>
    <ffd:OfferingSctyTp contextRef="offrl_7" id="ixv-659">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_7" id="ixv-660">Common Stock, par value $0.00001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule415a6Flg contextRef="offrl_7" id="ixv-661">true</ffd:Rule415a6Flg>
    <ffd:CfwdFormTp contextRef="offrl_7" id="ixv-662">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_7" id="ixv-663">333-268143</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_7" id="ixv-664">2022-11-08</ffd:CfwdPrrFctvDt>
    <ffd:OfferingSctyTp contextRef="offrl_8" id="ixv-665">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_8" id="ixv-666">Preferred Stock, par value $0.00001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule415a6Flg contextRef="offrl_8" id="ixv-667">true</ffd:Rule415a6Flg>
    <ffd:CfwdFormTp contextRef="offrl_8" id="ixv-668">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_8" id="ixv-669">333-268143</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_8" id="ixv-670">2022-11-08</ffd:CfwdPrrFctvDt>
    <ffd:OfferingSctyTp contextRef="offrl_9" id="ixv-671">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_9" id="ixv-672">Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule415a6Flg contextRef="offrl_9" id="ixv-673">true</ffd:Rule415a6Flg>
    <ffd:CfwdFormTp contextRef="offrl_9" id="ixv-674">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_9" id="ixv-675">333-268143</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_9" id="ixv-676">2022-11-08</ffd:CfwdPrrFctvDt>
    <ffd:OfferingSctyTp contextRef="offrl_10" id="ixv-677">Debt</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_10" id="ixv-678">Debt Securities</ffd:OfferingSctyTitl>
    <ffd:Rule415a6Flg contextRef="offrl_10" id="ixv-679">true</ffd:Rule415a6Flg>
    <ffd:CfwdFormTp contextRef="offrl_10" id="ixv-680">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_10" id="ixv-681">333-268143</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_10" id="ixv-682">2022-11-08</ffd:CfwdPrrFctvDt>
    <ffd:OfferingSctyTp contextRef="offrl_11" id="ixv-683">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_11" id="ixv-684">Units</ffd:OfferingSctyTitl>
    <ffd:Rule415a6Flg contextRef="offrl_11" id="ixv-685">true</ffd:Rule415a6Flg>
    <ffd:CfwdFormTp contextRef="offrl_11" id="ixv-686">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_11" id="ixv-687">333-268143</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_11" id="ixv-688">2022-11-08</ffd:CfwdPrrFctvDt>
    <ffd:OfferingSctyTp contextRef="offrl_12" id="ixv-689">Unallocated (Universal) Shelf</ffd:OfferingSctyTp>
    <ffd:Rule415a6Flg contextRef="offrl_12" id="ixv-690">true</ffd:Rule415a6Flg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_12"
      decimals="INF"
      id="ixv-691"
      unitRef="USD">35204683.00</ffd:MaxAggtOfferingPric>
    <ffd:CfwdFormTp contextRef="offrl_12" id="ixv-692">S-3</ffd:CfwdFormTp>
    <ffd:CfwdPrrFileNb contextRef="offrl_12" id="ixv-693">333-268143</ffd:CfwdPrrFileNb>
    <ffd:CfwdPrrFctvDt contextRef="offrl_12" id="ixv-694">2022-11-08</ffd:CfwdPrrFctvDt>
    <ffd:CfwdPrevslyPdFee
      contextRef="offrl_12"
      decimals="INF"
      id="ixv-695"
      unitRef="USD">3879.56</ffd:CfwdPrevslyPdFee>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="INF" id="ixv-696" unitRef="USD">150000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="INF" id="ixv-697" unitRef="USD">15853.23</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="INF" id="ixv-698" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="INF" id="ixv-699" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="INF" id="ixv-700" unitRef="USD">15853.23</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_6" id="ixv-701">1(a) Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities or preferred stock or upon exercise of warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $150,000,000. 1(b) An indeterminate amount of common stock, preferred stock, warrants, debt securities and/or units is being registered as may from time to time be offered hereunder at indeterminate prices, along with an indeterminate number of securities that may be issued upon exercise, settlement, exchange or conversion of securities offered or sold hereunder. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or pursuant to anti-dilution provisions of any of the securities. Separate consideration may or may not be received for securities that are issuable upon conversion, exercise or exchange of other securities. 1(c) The $150,000,000 of securities registered pursuant to this registration statement includes $50,000,000 of common stock that may be issued and sold under a certain sales agreement with B. Riley Securities, Inc. Upon termination of the sales agreement, any portion of the $50,000,000 included in the sales agreement prospectus supplement that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $50,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement. 1(d) Pursuant to Rule 415(a)(6) under the Securities Act, the securities registered pursuant to this registration statement include $35,204,683 of unsold securities (the "Unsold Securities") previously registered pursuant to the Registration Statement on Form S-3 (File No. 333-268143), which was declared effective on November 8, 2022 (the "Prior Registration Statement"). The registrant sold an aggregate of $14,795,317 of securities under the Prior Registration Statement, leaving the balance of $35,204,683 of Unsold Securities, in respect of which the registrant paid a filing fee of $3,879.56 (based on the filing fee rate in effect at the time of the filing of the Prior Registration Statement) in connection with the filing of the Prior Registration Statement. Pursuant to Rule 415(a)(6), the filing fee of $3,879.56 associated with the offering of the Unsold Securities is hereby carried forward to be applied to $35,204,683 of Unsold Securities registered hereunder, and as a result, no additional filing fee is due with respect to the Unsold Securities included in this registration statement. Pursuant to Rule 415(a)(6), the offering of securities under the Prior Registration Statement will be deemed terminated as of the time of effectiveness of this registration statement.</ffd:OfferingNote>
    <ffd:OfferingNote contextRef="offrl_12" id="ixv-702">See Offering Note 1(d)</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
